


# WEST Search History

DATE: Monday, August 30, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L15	L14 AND D-amino acid	132
<input type="checkbox"/>	L14	(amyloid-beta OR beta-amyloid OR abeta)	2989
<input type="checkbox"/>	L13	L12 AND D-amino acid	25
<input type="checkbox"/>	L12	L11 AND amyloid AND beta	207
<input type="checkbox"/>	L11	514/2.CCLS.	6232
<input type="checkbox"/>	L10	L9 AND D-amino acid	10
<input type="checkbox"/>	L9	L8 AND amyloid AND beta	33
<input type="checkbox"/>	L8	L6 AND beta-amyloid	33
<input type="checkbox"/>	L7	L6 AND abeta	5
<input type="checkbox"/>	L6	424/184.1,185.1,193.1.CCLS.	3828
<input type="checkbox"/>	L5	Schenk.IN.	2887
<input type="checkbox"/>	L4	Schenk-D.IN.	7
<input type="checkbox"/>	L3	Schenk-Dale.IN.	3
<input type="checkbox"/>	L2	Schenk-D-B.IN.	17
<input type="checkbox"/>	L1	(Schenk-Dale-B.IN.)	32

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
 Search PubMed for beta-amyloid AND D-amino acid Go Clear  
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text  
 Items 1-4 of 4 One page.

1: [Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I](#) Related Articles, Links

**Protective peptides that are orally active and mechanistically nonchiral.**  
 J Pharmacol Exp Ther. 2004 Jun;309(3):1190-7. Epub 2004 Mar 08.  
 PMID: 15007105 [PubMed - indexed for MEDLINE]

2: [Formaggio F, Bettio A, Moretto V, Crisma M, Toniolo C, Broxterman QR](#) Related Articles, Links

**Disruption of the beta-sheet structure of a protected pentapeptide, related to the beta-amyloid sequence 17-21, induced by a single, helicogenic C(alpha)-tetrasubstituted alpha-amino acid.**  
 J Pept Sci. 2003 Jul;9(7):461-6.  
 PMID: 12916643 [PubMed - indexed for MEDLINE]

3: [Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais F](#) Related Articles, Links

**Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide.**  
 J Biol Chem. 2003 Sep 12;278(37):34874-81. Epub 2003 Jul 02.  
 PMID: 12840031 [PubMed - indexed for MEDLINE]

4: [Blanchard BJ, Konopka G, Russell M, Ingram VM](#) Related Articles, Links

**Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.**  
 Brain Res. 1997 Nov 21;776(1-2):40-50.  
 PMID: 9439794 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search PubMed for **Alzheimers AND D-amino acid** Go Clear  
Limits Preview/Index History Clipboard Details

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

Display Summary Show: 500 Sort Send to Text  
Items 1-5 of 5 One page.

☐ 1: [Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D.](#) Related Articles, Links

Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display.  
ChemBiochem. 2003 Aug 4;4(8):748-53.  
PMID: 12898626 [PubMed - indexed for MEDLINE]

☐ 2: [Blanchard BJ, Konopka G, Russell M, Ingram VM.](#) Related Articles, Links

Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.  
Brain Res. 1997 Nov 21;776(1-2):40-50.  
PMID: 9439794 [PubMed - indexed for MEDLINE]

☐ 3: [Soto C, Kindy MS, Baumann M, Frangione B.](#) Related Articles, Links

Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation.  
Biochem Biophys Res Commun. 1996 Sep 24;226(3):672-80.  
PMID: 8831674 [PubMed - indexed for MEDLINE]

☐ 4: [Fisher GH, Petrucelli L, Gardner C, Emory C, Frey WH 2nd, Amaducci L, Sorbi S, Sorrentino G, Borghi M, D'Aniello A.](#) Related Articles, Links

Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects.  
Mol Chem Neuropathol. 1994 Oct-Dec;23(2-3):115-24.  
PMID: 7702702 [PubMed - indexed for MEDLINE]


☐ 5: [Fisher GH, D'Aniello A, Vetere A, Padula L, Cusano GP, Man EH.](#) Related Articles, Links

Free D-aspartate and D-alanine in normal and Alzheimer brain.  
Brain Res Bull. 1991 Jun;26(6):983-5.  
PMID: 1933416 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search PubMed for amyloid precursor protein AND D-amino acid Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

No items found.

Text Version

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

#### Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Welcome to STN International! Enter x:x  
\* \* \* \* \* Welcome to STN International \* \* \* \* \*  
\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:10:17 ON 30 AUG 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'AQUALINE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:10:27 ON 30 AUG 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:10:27 ON 30 AUG 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'CAPLUS' ENTERED AT 12:10:27 ON 30 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:10:27 ON 30 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'FOMAD' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'HEALSAFE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:10:27 ON 30 AUG 2004  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:10:27 ON 30 AUG 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:10:27 ON 30 AUG 2004  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:10:27 ON 30 AUG 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:10:27 ON 30 AUG 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:10:27 ON 30 AUG 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:10:27 ON 30 AUG 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:10:27 ON 30 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S D-amino acid  
15 FILES SEARCHED...  
25 FILES SEARCHED...  
41 FILES SEARCHED...  
59 FILES SEARCHED...  
67 FILES SEARCHED...

L1 35501 D-AMINO ACID

=> S Alzheimers OR beta-amyloid OR amyloid-beta OR amyloid precursor protein  
13 FILES SEARCHED...  
19 FILES SEARCHED...  
25 FILES SEARCHED...  
33 FILES SEARCHED...  
47 FILES SEARCHED...  
63 FILES SEARCHED...

L2 160285 ALZHEIMERS OR BETA-AMYLOID OR AMYLOID-BETA OR AMYLOID PRECURSOR  
PROTEIN

=> S L1 AND L2  
50 FILES SEARCHED...  
L3 685 L1 AND L2

=> DUP REM L3  
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,  
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,  
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L3  
L4 564 DUP REM L3 (121 DUPLICATES REMOVED)

=> S L4 AND beta-amyloid  
20 FILES SEARCHED...  
37 FILES SEARCHED...  
61 FILES SEARCHED...  
L5 367 L4 AND BETA-AMYLOID

=> D L5 1-367

L5 ANSWER 1 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV  
on STN  
ACCESSION NUMBER: 2004:204 ADISINSIGHT  
SOURCE: Adis R&D Insight  
DOCUMENT NO: 020334  
CHANGE DATE: Jun 25, 2004  
GENERIC NAME: Research programme: neuroprotective therapies - Allon  
Therapeutics  
SYNONYM: ADN-9; AL209; AL309; SAL; SALLRSIPA  
MOLECULAR FORMULA: Unspecified  
STRUCTURE:  
STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMA ATC CODE: N7X All other CNS drugs  
WHO ATC CODE: N07X Other Nervous System Drugs  
HIGHEST DEV. PHASE: Preclinical

COMPANY INFORMATION  
ORIGINATOR: Allon Therapeutics (United States)  
PARENT: Allon Therapeutics

WORD COUNT: 596

L5 ANSWER 2 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV  
on STN  
ACCESSION NUMBER: 2001:589 ADISINSIGHT  
SOURCE: Adis R&D Insight  
DOCUMENT NO: 015723  
CHANGE DATE: Jan 22, 2003  
GENERIC NAME: Research programme: huntingtin decoy peptides -  
Massachusetts Institute of Technology  
SYNONYM: Huntingtin decoy peptides research programme -  
Massachusetts Institute of Technology  
MOLECULAR FORMULA: Unspecified  
STRUCTURE:

EPHMRA ATC CODE: N7X All other CNS drugs  
WHO ATC CODE: N07X Other Nervous System Drugs  
HIGHEST DEV. PHASE: No Development Reported

COMPANY INFORMATION

ORIGINATOR: Nonindustrial source (United States)  
PARENT: Nonindustrial source

WORD COUNT: 142

L5 ANSWER 3 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV  
on STN

ACCESSION NUMBER: 2001:586 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 015715

CHANGE DATE: Jun 24, 2003

GENERIC NAME: \*\*\*Research programme: beta-amyloid decoy peptides -\*\*  
\*\*\* Massachusetts Institute of Technology\*\*\*

SYNONYM: \*\*\*Beta amyloid decoy peptides research programme -\*\*  
\*\*\* Massachusetts Institute of Technology\*\*\*

MOLECULAR FORMULA: Unspecified

STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products; N7X All other  
CNS drugs

WHO ATC CODE: N06D-X Other anti-dementia drugs; N07X Other Nervous  
System Drugs

HIGHEST DEV. PHASE: No Development Reported

COMPANY INFORMATION

ORIGINATOR: Massachusetts Institute of Technology (United States)

PARENT: Massachusetts Institute of Technology

OTHER: Amgen

WORD COUNT: 283

L5 ANSWER 4 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV  
on STN

ACCESSION NUMBER: 2000:1811 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 014948

CHANGE DATE: Jul 28, 2004

GENERIC NAME: AL 108

SYNONYM: ADNP-8; AL108; NAP; NAPVSIPO

CHEMICAL NAME: L-Asparaginy-L-alanyl-L-prolyl-L-valyl-L-seryl-L-  
isoleucyl-L-prolyl-L-glutamine

MOLECULAR FORMULA: C36 H60 N10 O12

STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products; N7X All other  
CNS drugs

WHO ATC CODE: N06D-X Other anti-dementia drugs; N07X Other Nervous  
System Drugs

HIGHEST DEV. PHASE: Preclinical

COMPANY INFORMATION

ORIGINATOR: Hadassah Medical Organization (Israel); Tel Aviv  
University (Israel); Allon Therapeutics (United States);  
National Institutes of Health (United States)

PARENT: Allon Therapeutics; Hebrew University of Jerusalem;  
National Institutes of Health (USA); Tel Aviv University

WORD COUNT: 1048

L5 ANSWER 5 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 2004:163974 BIOSIS

DN PREV200400167893

TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*

AU Findeis, Mark A. [Inventor, Reprint Author]; Gefter, Malcolm L.  
[Inventor]; Musso, Gary [Inventor]; Signer, Ethan R. [Inventor];

[Inventor]; Lee, Jung-Ja [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci, Sonja [Inventor]; Arico-Muendel, Christopher C. [Inventor]; Phillips, Kathryn [Inventor]; Hayward, Neil J. [Inventor]  
 CS ASSIGNEE: Praecis Pharmaceuticals, Incorporated, Waltham, MA, USA  
 PI US 6689752 February 10, 2004  
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Feb 10 2004) Vol. 1279, No. 2. <http://www.uspto.gov/web/menu/patdata.html>  
 . e-file.  
 ISSN: 0098-1133 (ISSN print).  
 DT Patent  
 LA English  
 ED Entered STN: 24 Mar 2004  
 Last Updated on STN: 24 Mar 2004

L5 ANSWER 6 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 2003:490981 BIOSIS  
 DN PREV200300493335  
 TI Stereoselective interactions of peptide inhibitors with the \*\*\*beta\*\*\*  
 - \*\*\*amyloid\*\*\* peptide.  
 AU Chalifour, Robert J.; McLaughlin, Richard W.; Lavoie, Louis; Morissette, Celine; Tremblay, Nadine; Boule, Marie; Sarazin, Philippe; Stea, Dino; Lacombe, Diane; Tremblay, Patrick; Gervais, Francine [Reprint Author]  
 CS Neurochem Inc., 7220, Frederick-Banting, Suite 100, Saint-Laurent, PQ, H4S 2A1, Canada  
 abstracts@neurochem.com  
 SO Journal of Biological Chemistry, (September 12 2003) Vol. 278, No. 37, pp. 34874-34881. print.  
 CODEN: JBCHA3. ISSN: 0021-9258.  
 DT Article  
 LA English  
 ED Entered STN: 22 Oct 2003  
 Last Updated on STN: 22 Oct 2003

L5 ANSWER 7 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 2003:477543 BIOSIS  
 DN PREV200300477543  
 TI Disruption of the beta-sheet structure of a protected pentapeptide, related to the \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* sequence 17-21, induced by a single, helicogenic Calpha-tetrasubstituted alpha-amino acid.  
 AU Formaggio, Fernando [Reprint Author]; Bettio, Andrea; Moretto, Vittorio; Crisma, Marco; Toniolo, Claudio; Broxterman, Quirinus B.  
 CS Department of Organic Chemistry, University of Padova, Via Marzolo I, 35131, Padova, Italy  
 fernando.formaggio@unipd.it  
 SO Journal of Peptide Science, (July 2003) Vol. 9, No. 7, pp. 461-466. print.  
 ISSN: 1075-2617 (ISSN print).  
 DT Article  
 LA English  
 ED Entered STN: 15 Oct 2003  
 Last Updated on STN: 15 Oct 2003

L5 ANSWER 8 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 2003:436021 BIOSIS  
 DN PREV200300436021  
 TI Modulators of mu-amyloid peptide aggregation.  
 AU Findeis, Mark A. [Inventor, Reprint Author]; Phillips, Kathryn [Inventor]; Olson, Gary L. [Inventor]; Self, Christopher [Inventor]  
 CS Boston, MA, USA  
 ASSIGNEE: Praecis Pharmaceuticals Inc.  
 PI US 6610658 August 26, 2003  
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug 26 2003) Vol. 1273, No. 4. <http://www.uspto.gov/web/menu/patdata.html>  
 . e-file.  
 ISSN: 0098-1133 (ISSN print).  
 DT Patent  
 LA English  
 ED Entered STN: 17 Sep 2003  
 Last Updated on STN: 17 Sep 2003

L5 ANSWER 9 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 2003:326954 BIOSIS

TI REGULATION OF SERINE RACEMASE AND D - SERINE PRODUCTION BY INFLAMMATORY  
 MEDIATORS AND HORMONES.  
 AU Wu, S. Z. [Reprint Author]; Bodles, A. M.; Porter, M. M.; Barger, S. W.  
 [Reprint Author]  
 CS Anatomy and neurobiology, Geriatrics, U. Arkansas Med.Sci, Little Rock,  
 AR, USA  
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)  
 Vol. 2002, pp. Abstract No. 784.15. <http://sfn.scholarone.com.cd-rom>.  
 Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.  
 Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.  
 DT Conference; (Meeting)  
 Conference; (Meeting Poster)  
 Conference; Abstract; (Meeting Abstract)  
 LA English  
 ED Entered STN: 16 Jul 2003  
 Last Updated on STN: 16 Jul 2003

L5 ANSWER 10 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 2001:572898 BIOSIS  
 DN PREV200100572898  
 TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
 comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 AU Findeis, Mark A. [Inventor]; Gefter, Malcolm L. [Inventor]; Musso, Gary  
 [Inventor]; Signer, Ethan R. [Inventor]; Wakefield, James [Inventor];  
 Molineaux, Susan [Inventor]; Chin, Joseph [Inventor]; Lee, Jung-Ja  
 [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci, Sonja [Inventor];  
 Arico-Muendel, Christopher C. [Inventor]; Phillips, Kathryn [Inventor];  
 Hayward, Neil J. [Inventor]  
 CS ASSIGNEE: Praecis Pharmaceuticals, Inc., Waltham, MA, USA  
 PI US 6303567 October 16, 2001  
 SO Official Gazette of the United States Patent and Trademark Office Patents,  
 (Oct. 16, 2001) Vol. 1251, No. 3. e-file.  
 CODEN: OGUPE7. ISSN: 0098-1133.  
 DT Patent  
 LA English  
 ED Entered STN: 12 Dec 2001  
 Last Updated on STN: 25 Feb 2002

L5 ANSWER 11 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 2001:479082 BIOSIS  
 DN PREV200100479082  
 TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
 comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 AU Findeis, Mark A. [Inventor]; Gefter, Malcolm L. [Inventor]; Musso, Gary  
 [Inventor]; Signer, Ethan R. [Inventor]; Wakefield, James [Inventor];  
 Reprint author; Molineaux, Susan [Inventor]; Chin, Joseph [Inventor];  
 Lee, Jung-Ja [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci,  
 Sonja [Inventor]; Arico-Muendel, Christopher C. [Inventor]; Phillips,  
 Kathryn [Inventor]; Hayward, Neil J. [Inventor]  
 CS Brookline, MA, USA  
 ASSIGNEE: Praecis Pharmaceuticals, Inc., Waltham, MA, USA  
 PI US 6277826 August 21, 2001  
 SO Official Gazette of the United States Patent and Trademark Office Patents,  
 (Aug. 21, 2001) Vol. 1249, No. 3. e-file.  
 CODEN: OGUPE7. ISSN: 0098-1133.  
 DT Patent  
 LA English  
 ED Entered STN: 10 Oct 2001  
 Last Updated on STN: 23 Feb 2002

L5 ANSWER 12 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 2000:292029 BIOSIS  
 DN PREV200000292029  
 TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
 comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 AU Findeis, Mark A. [Inventor, Reprint author]; Gefter, Malcolm L.  
 [Inventor]; Musso, Gary [Inventor]; Signer, Ethan R. [Inventor];  
 Wakefield, James [Inventor]; Molineaux, Susan [Inventor]; Chin, Joseph  
 [Inventor]; Lee, Jung-J [Inventor]; Kelley, Michael [Inventor];  
 Komar-Panicucci, Sonj [Inventor]; Arico-Muendel, Christopher C.  
 [Inventor]; Phillips, Kathryn [Inventor]; Hayward, Neil J. [Inventor]  
 CS North Grafton, MA, USA

PI US 5985242 November 16, 1999  
 SO Official Gazette of the United States Patent and Trademark Office Patents,  
 (Nov. 16, 1999) Vol. 1228, No. 3. e-file.  
 CODEN: OGUPE7. ISSN: 0098-1133.  
 DT Patent  
 LA English  
 ED Entered STN: 6 Jul 2000  
 Last Updated on STN: 7 Jan 2002

L5 ANSWER 13 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1998:80765 BIOSIS  
 DN PREV199800080765  
 TI Mechanism and prevention of neurotoxicity caused by \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptides: Relation to Alzheimer's disease.  
 AU Blanchard, Barbara J.; Konopka, Genevieve; Russell, Margaret; Ingram,  
 Vernon M. [Reprint author]  
 CS Dep. Biol., Massachusetts Inst. Technol., Cambridge, MA 02139, USA  
 SO Brain Research, (Nov. 21, 1997) Vol. 776, No. 1-2, pp. 40-50. print.  
 CODEN: BRREAP. ISSN: 0006-8993.  
 DT Article  
 LA English  
 ED Entered STN: 24 Feb 1998  
 Last Updated on STN: 24 Feb 1998

L5 ANSWER 14 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
 AN 2004-14623 BIOTECHDS  
 TI Identifying an agent that alters processing of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* precursor (APP) protein by contacting the agent with an  
 animal host cell that expresses APP and an APP processing enzyme and  
 detecting altered APP processing;  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\*  
 process alteration and transgenic animal for use in disease therapy  
 AU HAGEN F S; LANNFELT L; GELLERFORS P  
 PA BIOARCTIC NEUROSCIENCE AB; ICOGEN CORP  
 PI WO 2004041213 21 May 2004  
 AI WO 2003-US35294 4 Nov 2003  
 PRAI US 2002-424031 4 Nov 2002; US 2002-424031 4 Nov 2002  
 DT Patent  
 LA English  
 OS WPI: 2004-400523 [37]

L5 ANSWER 15 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
 AN 2004-09510 BIOTECHDS  
 TI Treating viral disease such as HIV, herpes simplex virus, varicella  
 zoster virus, poliomyelitis virus, cytomegalovirus, in subjects, involves  
 administering amyloidogenic peptide modulator compound to the subject;  
 for use in gene therapy and drug screening  
 AU ISRAEL D I; MIRZABEKOV T; WOJTIOWICZ W M; SODROSKI J  
 PA PRAECIS PHARM INC  
 PI WO 2003105677 24 Dec 2003  
 AI WO 2003-US19365 18 Jun 2003  
 PRAI US 2002-394390 8 Jul 2002; US 2002-390040 18 Jun 2002  
 DT Patent  
 LA English  
 OS WPI: 2004-169032 [16]

L5 ANSWER 16 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
 AN 2003-14872 BIOTECHDS  
 TI New Activity Dependent Neurotrophic Factor I complex polypeptide, useful  
 for reducing neuronal cell death, treating oxidative stress in a patient,  
 or improving learning and/or memory in a subject with e.g. Alzheimer's  
 disease;  
 protein and antibody useful for disease therapy and diagnosis  
 AU BRENNEMAN D E; CASTELLON R; SPONG C Y; HAUSER J M; GOZES I  
 PA UNIV RAMOT AT TEL AVIV LTD; US DEPT HEALTH and HUMAN SERVICES  
 PI WO 2003022226 20 Mar 2003  
 AI WO 2002-US29146 12 Sep 2002  
 PRAI US 2002-371961 10 Apr 2002; US 2001-322760 12 Sep 2001  
 DT Patent  
 LA English  
 OS WPI: 2003-354501 [33]

L5 ANSWER 17 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
 AN 2003-08134 BIOTECHDS



\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention and treatment of Alzheimer's disease;

\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide useful for Alzheimer disease therapy and diagnosis

AU WILLBOLD D; WIESEHAN K  
PA IMB INST MOLEKULARE BIOTECHNOLOGIE EV  
PI WO 2002081505 17 Oct 2002  
AI WO 2002-EP3862 8 Apr 2002  
PRAI DE 2001-1017281 6 Apr 2001; DE 2001-1017281 6 Apr 2001  
DT Patent  
LA German  
OS WPI: 2003-103321 [09]

L5 ANSWER 18 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
AN 2003-02087 BIOTECHDS  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an immunoglobulin heavy chain constant region linked to a peptide capable of binding amyloidogenic protein;

vector-mediated gene transfer, expression in host cell for recombinant protein production and disease therapy

AU GEFTER M L; ISRAEL D I; JOYAL J L; GOSSELIN M  
PA PRAECIS PHARM INC  
PI WO 2002042462 30 May 2002  
AI WO 2001-US44581 27 Nov 2001  
PRAI US 2000-257186 20 Dec 2000; US 2000-253302 27 Nov 2000  
DT Patent  
LA English  
OS WPI: 2002-636427 [68]

L5 ANSWER 19 OF 367 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN  
AN 2003:37010600 BIOTECHNO

TI Selection of \*\*\*D\*\*\* - \*\*\*amino\*\*\* - \*\*\*acid\*\*\* peptides that bind to Alzheimer's disease amyloid peptide A.beta..sub.1.sub.-.sub.4.sub.2 by mirror image phage display  
AU Wiesehan K.; Buder K.; Linke R.P.; Patt S.; Stoldt M.; Unger E.; Schmitt B.; Bucci E.; Willbold D.  
CS Dr. D. Willbold, Forschungszentrum Julich, IBI-2, 52425 Julich, Germany. E-mail: dieter.willbold@uni-duesseldorf.de  
SO ChemBioChem, (04 AUG 2003), 4/8 (748-753), 29 reference(s)  
CODEN: CBCHFX ISSN: 1439-4227  
DT Journal; Article  
CY Germany, Federal Republic of  
LA English  
SL English

L5 ANSWER 20 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:454464 CAPLUS  
DN 141:64409  
TI Protective peptides that are orally active and mechanistically nonchiral  
AU Brennenman, Douglas E.; Spong, Catherine Y.; Hauser, Janet M.; Abebe, Daniel; Pinhasov, Albert; Golian, Tania; Gozes, Illana  
CS Section on Developmental and Molecular Pharmacology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA  
SO Journal of Pharmacology and Experimental Therapeutics (2004), 309(3), 1190-1197

CODEN: JPETAB; ISSN: 0022-3565  
PB American Society for Pharmacology and Experimental Therapeutics  
DT Journal  
LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:496984 CAPLUS  
DN 140:72737  
TI Identification and characterization of a specific ligand for the Alzheimer \*\*\*amyloid\*\*\* -. \*\*\*beta\*\*\* -.peptide (A.beta.)  
AU Wiesehan, Katja  
CS Institut fuer Biologische Informationsverarbeitung, Forschungszentrum Juelich, Germany  
SO Berichte des Forschungszentrums Juelich (2003), Juel-4024, i-vii, 1-143  
CODEN: FJBEE5; ISSN: 0944-2952  
DT Report

RE.CNT 158 THERE ARE 158 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:190130 CAPLUS  
TI Designed helical peptides as gamma-secreatase inhibitors  
AU Das, Chittaranjan; Wolfe, Michael S.; Tsai, Jui-Yi; Diehl, Thekla S.  
CS Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard  
Medical school, Boston, MA, 02115, USA  
SO Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United  
States, April 7-11, 2002 (2002), MEDI-011 Publisher: American Chemical  
Society, Washington, D. C.  
CODEN: 69CKQP  
DT Conference; Meeting Abstract  
LA English

L5 ANSWER 23 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:628174 CAPLUS  
DN 133:221242  
TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
IN Findeis, Mark A.; Phillips, Kathryn; Olson, Gary L.; Self, Christopher  
PA Praecis Pharmaceuticals Incorporated, USA  
SO PCT Int. Appl., 87 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052048	A1	20000908	WO 2000-US5574	20000303
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1161449	A1	20011212	EP 2000-916028	20000303
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008738	A	20011226	BR 2000-8738	20000303
	JP 2002543043	T2	20021217	JP 2000-602272	20000303
	US 6610658	B1	20030826	US 2000-519019	20000303
	NZ 514414	A	20040227	NZ 2000-514414	20000303
	ZA 2001007913	A	20020926	ZA 2001-7913	20010926
	US 2003236197	A1	20031225	US 2003-395290	20030324
PRAI	US 1999-122736P	P	19990304		
	US 2000-519019	A1	20000303		
	WO 2000-US5574	W	20000303		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1998:163613 CAPLUS  
DN 128:217639  
TI Preparation of \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptides as  
modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
IN Findeis, Mark A.; Geffter, Malcolm L.; Musso, Gary; Signer, Ethan R.;  
Wakefield, James; Molineaux, Susan; Chin, Joseph; Lee, Jung-Ja; Kelley,  
Michael; Komar-Panicucci, Sonja; Arico-Muendel, Christopher C.; Phillips,  
Kathryn; Hayward, Neil J.  
PA Praecis Pharmaceuticals Incorporated, USA  
SO PCT Int. Appl., 92 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808868	A1	19980305	WO 1997-US15166	19970827
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,  
 YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

US	6303567	B1	20011016	US	1996-703675	19960827
AU	9742387	A1	19980319	AU	1997-42387	19970827
AU	741199	B2	20011122			
EP	929574	A1	19990721	EP	1997-940663	19970827
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP	2001500852	T2	20010123	JP	1998-511914	19970827
AU	759036	B2	20030403	AU	2000-35389	20000519
AU	769915	B2	20040212	AU	2002-15539	20020211
PRAI	US 1996-703675	A	19960827			
	US 1997-897342	A	19970721			
	US 1995-404831	A2	19950314			
	US 1995-475579	A2	19950607			
	US 1995-548998	B2	19951027			
	AU 1996-52524	A3	19960314			
	US 1996-616081	B2	19960314			
	AU 1997-42387	A3	19970827			
	WO 1997-US15166	W	19970827			
OS	MARPAT 128:217639					
RE.CNT	8					
	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD					
	ALL CITATIONS AVAILABLE IN THE RE FORMAT					

L5 ANSWER 25 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:490012 CAPLUS  
 TI Effects of racemization on the aggregational properties of the  
 \*\*\*amyloid\*\*\* . \*\*\*beta\*\*\* -peptide in Alzheimer's disease  
 AU Yang, Jing; Hong, Anita; Zagorski, Michael  
 CS Department Chemistry, Case Western Reserve University, Cleveland, OH,  
 44106, USA  
 SO Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, September  
 7-11 (1997), MEDI-255 Publisher: American Chemical Society, Washington, D.  
 C.  
 CODEN: 64RNAO  
 DT Conference; Meeting Abstract  
 LA English

L5 ANSWER 26 OF 367 CIN COPYRIGHT 2004 ACS on STN  
 AN 31(18):20204N CIN  
 TI Patents  
 SO Biotechnol. News, 12 Apr 2002 (20020412), 22(9), p. 12. ISSN: 0273-3226;  
 CODEN: BINWEY.  
 LA English

L5 ANSWER 27 OF 367 CIN COPYRIGHT 2004 ACS on STN  
 AN 31(8):8178Z CIN  
 TI Patents  
 SO Biotechnol. News, 1 Feb 2002 (20020201), 22(3), p. 12. ISSN: 0273-3226;  
 CODEN: BINWEY.  
 LA English

L5 ANSWER 28 OF 367 DISSABS COPYRIGHT (C) 2004 ProQuest Information and  
 Learning Company; All Rights Reserved on STN  
 AN 2001:43543 DISSABS Order Number: AAI9999583  
 TI Synthesis and evaluation of difluoro ketone peptidomimetic inhibitors to  
 investigate the intramembranous cleavage of \*\*\*amyloid\*\*\*  
 \*\*\*precursor\*\*\* and notch  
 AU Moore, Chad Leroy [Ph.D.]; Wolfe, Michael S. [adviser]  
 CS The University of Tennessee Center for the Health Sciences (0783)  
 SO Dissertation Abstracts International, (2001) Vol. 61, No. 12B, p. 6483.  
 Order No.: AAI9999583. 169 pages.  
 ISBN: 0-493-08021-X.  
 DT Dissertation  
 FS DAI  
 LA English

L5 ANSWER 29 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99468 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -

PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 55.

L5 ANSWER 30 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99467 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 54.

L5 ANSWER 31 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99466 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention.  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 53.

L5 ANSWER 32 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99465 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 52.

L5 ANSWER 33 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99464 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 51.

L5 ANSWER 34 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99463 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K

PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 50.

L5 ANSWER 35 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99462 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 49.

L5 ANSWER 36 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99461 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 48.

L5 ANSWER 37 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99460 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 47.

L5 ANSWER 38 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99459 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 46.

L5 ANSWER 39 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99458 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.

AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 45.

L5 ANSWER 40 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99457 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 44.

L5 ANSWER 41 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99456 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 43.

L5 ANSWER 42 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99455 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 42.

L5 ANSWER 43 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99454 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 41.

L5 ANSWER 44 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99453 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p

PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 40.

L5 ANSWER 45 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99452 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 39.

L5 ANSWER 46 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99451 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 38.

L5 ANSWER 47 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99450 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 37.

L5 ANSWER 48 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99449 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 36.

L5 ANSWER 49 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99448 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408

DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 35.

L5 ANSWER 50 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99447 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 34.

L5 ANSWER 51 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99446 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 33.

L5 ANSWER 52 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99445 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 32.

L5 ANSWER 53 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99444 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 31.

L5 ANSWER 54 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99443 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406



LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 30.

L5 ANSWER 55 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99442 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 29.

L5 ANSWER 56 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99441 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 28.

L5 ANSWER 57 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99440 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 27.

L5 ANSWER 58 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99439 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 26.

L5 ANSWER 59 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99438 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent

OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 25.

L5 ANSWER 60 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99437 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 24.

L5 ANSWER 61 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99436 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 23.

L5 ANSWER 62 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99435 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 22.

L5 ANSWER 63 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99434 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 21.

L5 ANSWER 64 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99433 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German

DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 20.

L5 ANSWER 65 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99432 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 19.

L5 ANSWER 66 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99431 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 18.

L5 ANSWER 67 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99430 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 17.

L5 ANSWER 68 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99429 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 16.

L5 ANSWER 69 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99428 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]

L5 ANSWER 70 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99427 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 14.

L5 ANSWER 71 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99426 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 13.

L5 ANSWER 72 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99425 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding L-form peptide 1.

L5 ANSWER 73 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99424 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 12.

L5 ANSWER 74 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99423 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 11.

L5 ANSWER 75 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99422 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 10.

L5 ANSWER 76 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99421 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 9.

L5 ANSWER 77 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99420 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 8.

L5 ANSWER 78 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99419 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 7.

L5 ANSWER 79 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP99418 Peptide DGENE  
 TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
 and treatment of Alzheimer's disease -  
 IN Willbold D; Wiesehan K  
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
 PI WO 2002081505 A2 20021017 28p  
 AI WO 2002-EP3862 20020408  
 PRAI DE 2001-10117281 20010406  
 DT Patent  
 LA German  
 OS 2003-103321 [09]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 6.

AN ABP99417 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 5.

L5 ANSWER 81 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99416 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 4.

L5 ANSWER 82 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99415 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 3.

L5 ANSWER 83 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99414 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 2.

L5 ANSWER 84 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN ABP99413 Peptide DGENE  
TI New \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* peptide specific for  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide, useful in diagnosis, prevention  
and treatment of Alzheimer's disease -  
IN Willbold D; Wiesehan K  
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.  
PI WO 2002081505 A2 20021017 28p  
AI WO 2002-EP3862 20020408  
PRAI DE 2001-10117281 20010406  
DT Patent  
LA German  
OS 2003-103321 [09]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* binding D-form peptide 1.

L5 ANSWER 85 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC Peptide #3 for analysis of \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* modulators  
 comprising D-residues.

L5 ANSWER 86 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12548 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC Peptide #2 for analysis of \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* modulators  
 comprising D-residues.

L5 ANSWER 87 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12547 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC Peptide #1 for analysis of \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* modulators  
 comprising D-residues.

L5 ANSWER 88 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12546 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 2001-637856 [73]

L5 ANSWER 89 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12539 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F19iodo Y).

L5 ANSWER 90 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12538 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19Y).

L5 ANSWER 91 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12537 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide.

L5 ANSWER 92 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12536 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]



L5 ANSWER 93 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12535 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19Y; F20Y).

L5 ANSWER 94 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12534 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (A21V).

L5 ANSWER 95 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12533 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (A21F).

L5 ANSWER 96 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12532 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]

L5 ANSWER 97 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12531 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (V18F; A21F).

L5 ANSWER 98 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12530 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant.

L5 ANSWER 99 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12529 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP 770 Abeta peptide (residues 18-21) retro inverso isomer.

L5 ANSWER 100 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12528 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]

L5 ANSWER 101 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12527 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F20iodo Y).

L5 ANSWER 102 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12526 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F20Y).

L5 ANSWER 103 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12525 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19iodo Y).

L5 ANSWER 104 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12524 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]

L5 ANSWER 105 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12523 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (L17A; A21L).

L5 ANSWER 106 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12522 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP 770 Abeta peptide (residues 17-21) inverso isomer.

L5 ANSWER 107 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12521 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F20A).

L5 ANSWER 108 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12520 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]

L5 ANSWER 109 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12519 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F19Y).

L5 ANSWER 110 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12518 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP 770 Abeta peptide (residues 17-20) inverso isomer #2.

L5 ANSWER 111 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12517 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]  
 DESC APP 770 Abeta peptide (residues 17-20) inverso isomer #1.

L5 ANSWER 112 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE12515 peptide DGENE  
 TI Modulator compound for treating disorders associated with  
 beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acids\*\*\*  
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
 K; Hayward N J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 6277826 B1 20010821 41p  
 AI US 1999-356931 19990719  
 PRAI US 1997-920162 19970827  
 US 1996-703675 19960827  
 DT Patent  
 LA English  
 OS 2001-637856 [73]

Abeta peptide (residues 17-20).

L5 ANSWER 113 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12514 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\*  
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
DT Patent  
LA English  
OS 2001-637856 [73]  
DESC APP 770 Abeta peptide retro inverso isomer mutant (A21F).

L5 ANSWER 114 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12513 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\*  
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
DT Patent  
LA English  
OS 2001-637856 [73]  
DESC APP 770 Abeta peptide retro inverso isomer mutant (A21L).

L5 ANSWER 115 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12512 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\*  
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
DT Patent  
LA English  
OS 2001-637856 [73]  
DESC APP 770 Abeta peptide retro inverso isomer mutant (V18L).

L5 ANSWER 116 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12511 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\*  
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
DT Patent  
LA English

DESC APP 770 Abeta peptide (residues 17-21) retro inverso isomer.

L5 ANSWER 117 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12510 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
(PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
OT Patent  
LA English  
OS 2001-637856 [73]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\*  
Abeta peptide (residues 17-21).

L5 ANSWER 118 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12509 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
(PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
OT Patent  
LA English  
OS 2001-637856 [73]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\*  
(APP-770) fragment.

L5 ANSWER 119 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAE12508 peptide DGENE  
TI Modulator compound for treating disorders associated with  
beta-amyloidosis e.g. Alzheimer's disease, comprises a \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide containing \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
\*\*\*acids\*\*\* -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;  
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips  
K; Hayward N J  
(PRAE-N) PRAECIS PHARM INC.  
PI US 6277826 B1 20010821 41p  
AI US 1999-356931 19990719  
PRAI US 1997-920162 19970827  
US 1996-703675 19960827  
OT Patent  
LA English  
OS 2001-637856 [73]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide (AP) of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\* (APP-770).

L5 ANSWER 120 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB62806 peptide DGENE  
TI Chemical compound/composition for e.g. treating neurodegenerative  
diseases, comprises peptide comprising Nalpha substituted alpha- \*\*\*D\*\*\*  
- \*\*\*amino\*\*\* - \*\*\*acid\*\*\* residues which inhibit the aggregation of  
other proteins/peptides into beta-sheet -  
IN Stott K  
PA (STOT-I) STOTT K.  
PI WO 2001007474 A1 20010201 76p  
AI WO 2000-GB2923 20000728  
PRAI GB 1999-17725 19990728  
OT Patent  
LA English

DESC Peptide X version 2 used to inhibit \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation.

L5 ANSWER 121 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB62805 peptide DGENE  
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- \*\*\*D\*\*\* - \*\*\*amino\*\*\* - \*\*\*acid\*\*\* residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K  
PA (STOT-I) STOTT K.  
PI WO 2001007474 A1 20010201 76p  
AI WO 2000-GB2923 20000728  
PRAI GB 1999-17725 19990728  
DT Patent  
LA English  
OS 2001-168537 [17]

DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide related amino acid sequence.

L5 ANSWER 122 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB62804 peptide DGENE  
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- \*\*\*D\*\*\* - \*\*\*amino\*\*\* - \*\*\*acid\*\*\* residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K  
PA (STOT-I) STOTT K.  
PI WO 2001007474 A1 20010201 76p  
AI WO 2000-GB2923 20000728  
PRAI GB 1999-17725 19990728  
DT Patent  
LA English  
OS 2001-168537 [17]

DESC Peptide X used to inhibit \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation.

L5 ANSWER 123 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB62803 peptide DGENE  
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- \*\*\*D\*\*\* - \*\*\*amino\*\*\* - \*\*\*acid\*\*\* residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K  
PA (STOT-I) STOTT K.  
PI WO 2001007474 A1 20010201 76p  
AI WO 2000-GB2923 20000728  
PRAI GB 1999-17725 19990728  
DT Patent  
LA English  
OS 2001-168537 [17]

DESC Residues 16-20 of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide.

L5 ANSWER 124 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY56104 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -

IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 5985242 A 19991116 40p  
AI US 1997-920162 19970827  
PRAI US 1995-548998 19951027  
US 1996-616081 19960314  
US 1996-703675 19960827  
US 1997-897342 19970721  
DT Patent  
LA English  
OS 2000-022266 [02]

DESC Peptide SEQ ID NO:31.

L5 ANSWER 125 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY56103 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying



Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC \*\*\*Beta\*\*\* \*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\*  
 APP-770 peptide sequence from 672.

L5 ANSWER 126 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY56102 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide 43 amino acid sequence.

L5 ANSWER 127 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY56101 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating compound #8.

L5 ANSWER 128 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY50000 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English

DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating compound #7.

L5 ANSWER 129 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY49999 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 5985242 A 19991116 40p  
AI US 1997-920162 19970827  
PRAI US 1995-548998 19951027  
US 1996-616081 19960314  
US 1996-703675 19960827  
US 1997-897342 19970721  
DT Patent  
LA English  
OS 2000-022266 [02]  
DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating compound #6.

L5 ANSWER 130 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY49998 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 5985242 A 19991116 40p  
AI US 1997-920162 19970827  
PRAI US 1995-548998 19951027  
US 1996-616081 19960314  
US 1996-703675 19960827  
US 1997-897342 19970721  
DT Patent  
LA English  
OS 2000-022266 [02]  
DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating compound #5.

L5 ANSWER 131 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY49997 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI US 5985242 A 19991116 40p  
AI US 1997-920162 19970827  
PRAI US 1995-548998 19951027  
US 1996-616081 19960314  
US 1996-703675 19960827  
US 1997-897342 19970721  
DT Patent  
LA English  
OS 2000-022266 [02]  
DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating compound #4.

L5 ANSWER 132 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAY49996 peptide DGENE  
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
PA (PRAE-N) PRAECIS PHARM INC.

AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #3.
L5	ANSWER 133 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49995 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #2.
L5	ANSWER 134 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49994 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #1.
L5	ANSWER 135 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49993 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #21.
L5	ANSWER 136 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		

TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #20.

L5 ANSWER 137 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49991 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #19.

L5 ANSWER 138 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49990 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #18.

L5 ANSWER 139 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49989 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #17.

L5 ANSWER 140 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49988 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721

DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #16.

L5 ANSWER 141 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49987 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721

DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #15.

L5 ANSWER 142 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49986 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721

DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #14.

L5 ANSWER 143 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49985 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso

C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #13.

L5 ANSWER 144 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49984 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #12.

L5 ANSWER 145 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49983 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #11.

L5 ANSWER 146 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49982 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating

L5 ANSWER 147 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49981 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #9.

L5 ANSWER 148 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49980 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #8.

L5 ANSWER 149 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49979 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #7.

L5 ANSWER 150 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49978 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827

	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #6.
L5	ANSWER 151 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49977 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #5.
L5	ANSWER 152 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49976 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #4.
L5	ANSWER 153 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49975 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #3.
L5	ANSWER 154 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49974 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying		



Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #2.  
 L5 ANSWER 155 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAY49973 peptide DGENE  
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -  
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI US 5985242 A 19991116 40p  
 AI US 1997-920162 19970827  
 PRAI US 1995-548998 19951027  
 US 1996-616081 19960314  
 US 1996-703675 19960827  
 US 1997-897342 19970721  
 DT Patent  
 LA English  
 OS 2000-022266 [02]  
 DESC Natural \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide aggregation modulating peptide #1.  
 L5 ANSWER 156 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27046 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #24.  
 L5 ANSWER 157 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27045 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #23.  
 L5 ANSWER 158 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27044 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.

AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #22.

L5 ANSWER 159 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27043 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #21.

L5 ANSWER 160 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27042 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #20.

L5 ANSWER 161 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27041 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #19.

L5 ANSWER 162 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27040 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #18.

L5 ANSWER 163 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27039 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p

PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #17.

L5 ANSWER 164 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27038 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #16.

L5 ANSWER 165 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27037 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #15.

L5 ANSWER 166 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27036 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #14.

L5 ANSWER 167 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27035 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #13.

L5 ANSWER 168 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27034 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303

T Patent  
A English  
S 2000-594168 [56]  
ESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #12.

5 ANSWER 169 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
N AAB27033 Peptide DGENE  
I Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
N Findeis M A; Phillips K; Olson G L; Self C  
A (PRAE-N) PRAECIS PHARM INC.  
I WO 2000052048 A1 20000908 87p  
I WO 2000-US5574 20000303  
RAI US 1999-122736 19990304  
T Patent  
A English  
S 2000-594168 [56]  
ESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #11.

5 ANSWER 170 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
N AAB27032 Peptide DGENE  
I Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
N Findeis M A; Phillips K; Olson G L; Self C  
A (PRAE-N) PRAECIS PHARM INC.  
I WO 2000052048 A1 20000908 87p  
I WO 2000-US5574 20000303  
RAI US 1999-122736 19990304  
T Patent  
A English  
S 2000-594168 [56]  
ESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #10.

5 ANSWER 171 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
N AAB27031 Peptide DGENE  
I Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
N Findeis M A; Phillips K; Olson G L; Self C  
A (PRAE-N) PRAECIS PHARM INC.  
I WO 2000052048 A1 20000908 87p  
I WO 2000-US5574 20000303  
RAI US 1999-122736 19990304  
T Patent  
A English  
S 2000-594168 [56]  
ESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #9.

5 ANSWER 172 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
N AAB27030 Peptide DGENE  
I Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
N Findeis M A; Phillips K; Olson G L; Self C  
A (PRAE-N) PRAECIS PHARM INC.  
I WO 2000052048 A1 20000908 87p  
I WO 2000-US5574 20000303  
RAI US 1999-122736 19990304  
T Patent  
A English  
S 2000-594168 [56]  
ESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #8.

5 ANSWER 173 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
N AAB27029 Peptide DGENE  
I Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
N Findeis M A; Phillips K; Olson G L; Self C  
A (PRAE-N) PRAECIS PHARM INC.  
I WO 2000052048 A1 20000908 87p  
I WO 2000-US5574 20000303  
RAI US 1999-122736 19990304

LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #7.

L5 ANSWER 174 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27028 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #6.

L5 ANSWER 175 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27027 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #5.

L5 ANSWER 176 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27026 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #4.

L5 ANSWER 177 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27025 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent  
 LA English  
 OS 2000-594168 [56]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #3.

L5 ANSWER 178 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB27024 Peptide DGENE  
 TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
 \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
 IN Findeis M A; Phillips K; Olson G L; Self C  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2000052048 A1 20000908 87p  
 AI WO 2000-US5574 20000303  
 PRAI US 1999-122736 19990304  
 DT Patent

OS 2000-594168 [56]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #2.

L5 ANSWER 179 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB27023 peptide DGENE  
TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
IN Findeis M A; Phillips K; Olson G L; Self C  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2000052048 A1 20000908 87p  
AI WO 2000-US5574 20000303  
PRAI US 1999-122736 19990304  
DT Patent  
LA English  
OS 2000-594168 [56]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide modulator #1.

L5 ANSWER 180 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB27022 protein DGENE  
TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
IN Findeis M A; Phillips K; Olson G L; Self C  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2000052048 A1 20000908 87p  
AI WO 2000-US5574 20000303  
PRAI US 1999-122736 19990304  
DT Patent  
LA English  
OS 2000-594168 [56]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation core domain #2.

L5 ANSWER 181 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB27021 protein DGENE  
TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
IN Findeis M A; Phillips K; Olson G L; Self C  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2000052048 A1 20000908 87p  
AI WO 2000-US5574 20000303  
PRAI US 1999-122736 19990304  
DT Patent  
LA English  
OS 2000-594168 [56]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation core domain #1.

L5 ANSWER 182 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB27020 protein DGENE  
TI Novel compounds that are useful as modulators of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide aggregation in treating amyloidosis, comprises  
\*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\* -  
IN Findeis M A; Phillips K; Olson G L; Self C  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2000052048 A1 20000908 87p  
AI WO 2000-US5574 20000303  
PRAI US 1999-122736 19990304  
DT Patent  
LA English  
OS 2000-594168 [56]  
DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* peptide.

L5 ANSWER 183 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51346 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #29 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 184 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51345 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #28 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 185 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51344 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #27 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 186 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51343 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #26 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 187 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51342 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #25 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 188 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51341 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #24 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 189 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51339 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #22 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 190 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51338 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #21 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 191 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51337 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721



DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #20 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 192 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51336 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #19 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 193 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51335 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #18 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 194 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51333 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #16 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 195 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51332 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #15 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 196 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51331 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #14 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 197 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51330 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #13 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 198 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51323 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #6 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 199 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51334 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #17 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 200 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51329 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #12 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 201 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51328 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #11 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 202 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51327 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #10 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 203 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51326 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #9 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 204 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51324 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #7 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 205 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51322 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #5 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 206 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51321 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #4 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 207 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51320 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #3 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 208 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51319 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #2 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 209 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51318 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Peptide #1 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide aggregation.

L5 ANSWER 210 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51317 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721  
US 1996-703675 19960827

DT Patent  
LA English  
OS 1998-216936 [19]  
DESC Natural \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide-770, from position 672  
to C-terminus.

L5 ANSWER 211 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAW51316 peptide DGENE  
TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relat  
to beta-amyloidosis, especially Alzheimer's disease  
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
R; Wakefield J  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 9808868 A1 19980305 92p  
AI WO 1997-US15166 19970827  
PRAI US 1997-897342 19970721

DT Patent  
 LA English  
 OS 1998-216936 [19]  
 DESC Natural \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide fragment.

L5 ANSWER 212 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAW51340 peptide DGENE  
 TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
 to beta-amyloidosis, especially Alzheimer's disease  
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
 R; Wakefield J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 9808868 A1 19980305 92p  
 AI WO 1997-US15166 19970827  
 PRAI US 1997-897342 19970721  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 1998-216936 [19]  
 DESC Peptide #23 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
 peptide aggregation.

L5 ANSWER 213 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAW51325 peptide DGENE  
 TI Peptide compounds which are preferably based on \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide(s) - are useful in treatment of disorders relate  
 to beta-amyloidosis, especially Alzheimer's disease  
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley  
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E  
 R; Wakefield J  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 9808868 A1 19980305 92p  
 AI WO 1997-US15166 19970827  
 PRAI US 1997-897342 19970721  
 US 1996-703675 19960827

DT Patent  
 LA English  
 OS 1998-216936 [19]  
 DESC Peptide #7 useful as modulator of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
 peptide aggregation.

L5 ANSWER 214 OF 367 FEDRIP COPYRIGHT 2004 NTIS on STN  
 AN 2004:141711 FEDRIP  
 NR CRISP 5R44AG17787-03  
 TI Inhibitors of Alzheimer's Disease Amyloidosis  
 SF Principal Investigator: CASTILLO, GERARDO M; CASTILLO@PROTEOTECH.COM,  
 PROTEOTECH, INC, 12026 115TH AVE NE  
 CSP PROTEOTECH, INC., KIRKLAND, WASHINGTON  
 CSS Supported By: NATIONAL INSTITUTE ON AGING  
 DB 2004 (/01/00)  
 FYR 2003  
 DE 2005 (/31/05)  
 FU Noncompeting Continuation (Type 5)  
 FS National Institutes of Health

L5 ANSWER 215 OF 367 FEDRIP COPYRIGHT 2004 NTIS on STN  
 AN 2004:140378 FEDRIP  
 NR CRISP 1Z01AG00408-04  
 TI TOXICITY OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* IN ALZHEIMER'S DISEASE AND  
 DOWN SYNDROME  
 SF Principal Investigator: GALDZICKI, Z  
 CSS Supported By: NATIONAL INSTITUTE ON AGING  
 FYR 1997  
 FU Not Applicable  
 FS National Institutes of Health

L5 ANSWER 216 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 10491766 IFIPAT;IFIUDB;IFICDB  
 TI MODULATORS OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* PEPTIDE AGGREGATION  
 IN Findeis Mark A; Olson Gary L; Phillips Kathryn; Self Christopher  
 PA Praecis Pharmaceuticals Inc (46269)  
 PI US 2003236197 A1 20031225  
 AI US 2003-395290 20030324

PRAI US 1999-122736P 19990304 (Provisional)  
FI US 2003236197 20031225  
US 6610658  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
CLMN 14  
GI 2 Figure(s).

FIG. 1 is a table depicting the results from a brain uptake assay.  
FIG. 2 is a graph depicting the results from the fibril binding assay described in Example 2.

L5 ANSWER 217 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
AN 10442451 IFIPAT;IFIUDB;IFICDB  
TI HELICAL PEPTIDOMIMETICS  
IN Wolfe Michael S  
PA Brigham and Women's Hospital (8822)  
PI US 2003186877 A1 20031002  
AI US 2003-367599 20030214  
PRAI US 2002-357023P 20020214 (Provisional)  
FI US 2003186877 20031002  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION

CLMN 46  
GI 1 Figure(s).

FIG. 1 is a schematic diagram showing various cleavage sites and fragments of APP. Among the fragments are A beta (including A beta 40 and A beta 42).

L5 ANSWER 218 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
AN 10408140 IFIPAT;IFIUDB;IFICDB  
TI VITRO MICRO-ORGANS, AND USES RELATED THERETO  
IN Mitrani Eduardo N (IL)  
PI US 2003152562 A1 20030814  
AI US 2003-376506 20030303  
RLI WO 2001-IL976 20011023 CONTINUATION  
FI US 2003152562 20030814  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION

CLMN 73  
GI 18 Figure(s).

FIG. 1 is a diagrammatic representation of a micro-organ depicting the dimensions that determine Aleph where  $x$ =thickness and  $a$ =width of tissue.

FIG. 2 is a histogram showing cell proliferation in a guinea pig micro-organ culture as determined by BrdU labeling after incubation for different time periods.

FIG. 3 is a histogram showing cell proliferation in a human back skin micro-organ culture as determined by BrdU labeling after incubation of cultures for 1-8 days.

FIGS. 4A-4D are micrographs showing immunofluorescence corresponding to replicating cells of mouse skin (mag. 50 x) (FIG. 4A), guinea pig skin (mag. 75 x) (FIG. 4B) human foreskin (mag. 50 x) (FIG. 4C) and human foreskin (mag. 75 x) (FIG. 4D).

FIGS. 5A-5C are transverse sections of human epidermal microorgan explants. (mag x 75) showing tissue architecture at zero (FIG. 5A), three (FIG. 5B) and six (FIG. 6D) days in culture.

FIG. 6 is a histogram demonstrating the effect on epidermal proliferation of varying thickness ( $x$ ) of guinea pig skin microorgan cultures using BrdU incorporation where ( $a$ ) has been kept constant at 4 mm.

FIGS. 7A-7B are micrographs showing immunofluorescence corresponding to proliferating cells in pancreas-derived microorgan cultures (mag 75 x).

FIG. 8 is a histogram showing amounts of insulin released by adult pig pancreas micro-organ cultures.

FIG. 9 is a histogram showing 3H-Thymidine incorporation in proliferating cells in micro-organ cultures of the colon, liver, kidney, duodenum and esophagus, at three days, four days and six days of culture.

FIGS. 10A-10C are micrographs showing active proliferation of hair follicles in micro-organ cultures as determined by immunofluorescence. Magnification 40 x (FIG. 10A), 40 x (FIG. 10B), and 75 x (FIG. 10C).

FIG. 11 is a histogram showing the size distribution of hair shafts at the beginning and end of the microculture.

FIG. 12 is a histogram showing the inhibition of mitogenesis in micro-organ cultures in the presence of 2.5 ng/ml TGF-beta in guinea-pig

FIG. 13 is a diagrammatic representation of a micro-organ explant for treatment of chronic skin ulcers showing incomplete sectioning of tissue slices so as to maintain a structure that can be readily manipulated in vivo.

FIG. 14 is a photograph of the surface of a mouse after replacement of a piece of normal skin with a micro-organ culture; healing, generation of new hair shafts in the implant, and incorporation of the implant into the normal mouse skin can be observed (mag 10 x).

FIG. 15 is a graphic representation of the expression of a luciferase reporter gene in a guinea pig skin micro-organ culture after transfection (of the culture with a plasmid encoding the luciferase reporter gene).

FIG. 16 is a graphic representation of the expression of a luciferase gene in rat lung and thymus micro-organ cultures after cationic lipid mediated transfection of the culture with plasmid encoding the luciferase reporter gene.

FIG. 17 is a graphic representation of the activation of telogen follicles upon treatment with FGF in micro-organ cultures of the present invention.

FIG. 18 is a graphic representation of the expression of a transgenic luciferase gene in micro-organ explants of the present invention.

L5 ANSWER 219 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
AN 10342993 IFIPAT;IFIUDB;IFICDB  
TI PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR TREATMENT OF  
DISORDERS OR DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO  
AMYLOID OR AMYLOID-LIKE DEPOSITS; INHIBITORY PEPTIDE FOR USE IN THE  
TREATMENT, PREVENTION AND DIAGNOSIS ALZHEIMER'S AND BRAIN DISORDERS  
IN Baumann Marc H (FI); Frangione Blas; Soto-Jara Claudio  
PA New York University (59449)  
PI US 2003087407 A1 20030508  
AI US 2002-235483 20020906  
RLI US 1996-766596 19961212 CONTINUATION 6462171  
US 1995-478326 19950607 CONTINUATION-IN-PART ABANDONED  
US 1996-630645 19960410 CONTINUATION-IN-PART 5948763  
FI US 2003087407 20030508  
US 6462171  
US 5948763  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION

CLMN 8  
GI

27 Figure(s).

FIGS. 1A-B provide a consensus sequence for amyloidogenesis in terms of hydrophobicity and secondary structure properties. FIG. 1A is the primary structure of the amyloidogenic sequence of peptides involved in the formation of several amyloid deposits. The sequences correspond to:  
\*\*\*amyloid\*\*\* \*\*\*beta\*\*\* -peptide (SEQ ID NO: 1) found in Alzheimer's disease, its Dutch variant and Downs Syndrome; amyloid A (SEQ ID NO: 2) found in secondary amyloidosis and familial Mediterranean fever; gelsolin amyloid (SEQ ID NO: 3) related to familial amyloidosis of Finnish type; amyloid L (SEQ ID NO: 4) found in immunoglobulin-related primary amyloidosis; beta 2-microglobulin amyloid (SEQ ID NO: 5) found in patients with chronic hemodialysis-related amyloidosis; and apolipoprotein A1 amyloid (SEQ ID NO: 6) related to familial amyloidotic polyneuropathy. Amino acids written in bold correspond to hydrophobic residues and those underlined represent positions with mutation related to the hereditary form of the disease. FIG. 1B provides the betasheet prediction for the 15 amino acid fragments containing the sequences shown in FIG. 1A. The solid bar represents regions with a high probability of adopting a beta-sheet structure.

FIGS. 2A-B provide the amino acid sequence for several anti-amyloid peptides. FIG. 2A shows the amino acid sequences four anti-amyloid peptides labeled as anti-amyloid 1 (SEQ ID NO: 7), anti-amyloid 2 (SEQ ID NO: 8), anti-amyloid 3 (SEQ ID NO: 9) and anti-amyloid 4 (SEQ ID NO: 10). Hydro-phobic amino acids are highlighted in bold. FIG. 2B shows the circular dichroism spectrum of the anti-amyloid peptide 1 (SEQ ID NO: 7) recorded as described in Example 1.

FIG. 3 is a schematic representation of the beta-cross conformation for amyloid fibrils showing the crucial importance of the interactions by hydrogen bonding between the monomeric beta-strand to form the intermolecular beta-cross structure.

FIGS. 4A-B show the effect of anti-amyloid peptide 2 having the sequence of SEQ ID NO: 8 on the amyloid formation by A beta in vitro. Amyloid formation was quantitated by the fluorometric assay described in Example 1. FIG. 4A shows the dose-dependent inhibition of amyloidogenesis, using anti-amyloid peptide 2 (shown as filled squares) and a 12 amino acid-non



time was 24 hours at room temperature and the A beta concentration was 1 mg/ml in 0.1 M Tris, pH 7.4. FIG. 4B shows the effect of anti-amyloid peptide 2 (SEQ ID NO: 8) on the amyloid formation after various incubation times.

The inhibitory effect of the peptide remained unaltered over several days of incubation. Incubations containing A beta, alone, are depicted by unfilled squares; incubations of A beta, and a control peptide are depicted by unfilled circles; and incubations of A beta and anti-amyloid peptide 2 are depicted by filled squares. The A beta concentration used was 1 mg/ml incubated in a molar ratio of anti-amyloid peptide 2 or control peptide of 1:20. Neither the anti-amyloid peptide 2 nor the control peptide gave fluorescence values over the background level of 1-2 fluorescence units.

FIGS. 5A-C show electron micrographs of negative-stained preparations of A beta (FIG. 5A), A beta incubated with anti-amyloid peptide 1 (SEQ ID NO: 7: FIG. 5B) and anti-amyloid peptide 1 alone (FIG. 5C). Aliquots of A beta were incubated at 1 mg/ml with or without the anti-amyloid peptide 1 in a molar ratio 1:50 (A beta :anti-amyloid) for 6 days at room temperature.

FIGS. 6A-B show the effects of anti-amyloid peptide 1 on the redissolution of preformed fibrils. Amyloid fibrils were formed by incubating A beta (1 mg/ml) for 3 days at room temperature. Anti-amyloid peptide 1 was then added in a molar ratio 1:50 (A beta :anti-amyloid peptide 1). The incubation was continued for 15 minutes, 6 hours or 24 hours and the amyloid formation was quantitated by the fluorometric assay (FIG. 6A). Fluorescence values represent the amount of amyloid formed. FIG. 6B provides electron micrographs of the nonincubated (left side picture) and incubated fibrils for 24 hours with anti-amyloid peptide 1 (right side picture). Magnification is 50,000 x.

FIGS. 7A-C show the physio-chemical characterization of the amphotericin (HMG-1) derived amyloid fragment, ATNp. FIG. 7A provides the amino acid sequence of the fragment ATNp (SEQ ID NO: 11). Hydrophobic amino acid residues are highlighted in bold. FIG. 7B shows the Chou-Fasman prediction for beta-sheet structure of ATNp. The sequence with the highest beta-sheet structure probability is indicated with a bar. FIG. 7C is an electron micrograph of negative-stained preparations of ATNp with formed amyloid-like fibrils.

FIG. 8 is a bar graph showing the effect of anti-amyloid peptide 1 on the amyloid formation by A beta and of peptides derived from the amyloidogenic sequence of gelsolin amyloid and amyloid A. Either A beta or the fifteen amino acid peptides containing the amyloidogenic sequence of gelsolin amyloid (SEQ ID NO: 12) and amyloid A (SEQ ID NO: 13) were incubated in a concentration of 1 mg/ml for 24 hours without and with anti-amyloid peptide 1 in a molar ratio of 1:5 or 1:20.

FIG. 9 shows the structural characteristics of anti-amyloid peptide 2 (iA beta). The amino acid sequence and beta-sheet probability for iA beta (SEQ ID NO: 8) and for the region of A beta (SEQ ID NO: 14) used as a template for iA beta is shown underneath the beta-sheet probability profile where the solid bar represents the region of A beta having a high probability of beta-sheet structure.

FIG. 10 shows the circular dichroism spectra of iA beta at different peptide concentration.

FIG. 11 shows the A beta-iA beta interaction as quantitated by the quenching of the intrinsic fluorescence of A beta (tyrosine 10) induced by the binding of iA beta. The inset shows the fluorescence spectra of A beta incubated alone or in the presence of 4 mu M iA beta.

FIG. 12 shows the dose-dependent inhibition of A beta 1-40 and A beta 1-42 fibrillogenesis by iA beta. \*\*\*beta\*\*\*. \*\*\*Amyloid\*\*\* formation was quantitated by the fluorometric assay, as described in Example 1. The A beta concentration was 1 mg/ml in 0.1M Tris, pH 7.6 and an incubation time of 24 h.

FIG. 13 shows the effect of iA beta on amyloid formation by A beta 1-40, after different incubation periods. The molar ratio A beta :iA beta (or control) was 1:20; A beta concentration 1 mg/ml. Amyloid formation was quantitated as in FIG. 12. iA beta or the control peptide alone did not give fluorescence values above the background level.

FIGS. 14A and 14B shows the dissolution of preformed A beta fibrils by iA beta in vitro. Amyloid fibrils were first preformed by incubating A beta 1-40 or A beta 1-42 at a concentration of 1 mg/ml for 6 days at room temperature. Fluorometric quantitation of amyloid as described in Example 1. FIG. 14A shows the effect of different molar ratios of iA beta or control peptide on fibril disassembly after 24 h of incubation. FIG. 14B fibril dissolution induced by a 40-fold molar excess of iA beta or control peptide after different incubation periods at room temperature.

FIGS. 15a-f shows the electron microscopy analysis of the effect of iA

mg/ml) were incubated at 37 degrees C. with or without iA beta or control peptide at a molar ratio 1:40 (A beta :iA beta), centrifuged and the pellet loaded on electron microscopy grids, stained and visualized as described in the Materials and Methods. FIG. 15a shows A beta incubated for 6 days; FIG. 15b shows A beta incubated with iA beta for 6 days; FIG. 15c shows A beta incubated alone for 5 days and then for 1 day with iA beta; FIG. 15d shows iA beta incubated for 6 days at the same concentration as in FIGS. 15b and c; FIG. 15e shows A beta incubated with the control peptide for 6 days; and FIG. 15f shows control peptide incubated alone for 6 days at the same concentration used in FIG. 15e. FIG. 16 shows the inhibition of amyloid formation after long period of incubation (days) in the presence of low concentrations of iA beta. 30 mu g of A beta 1-42 was incubated in 30 mu l of 0.1M tris, pH 7.4 with a molar ratio 1:5 (A beta :iA beta) of the inhibitor for different times at room temperature. Amyloid was quantitated by the thioflavine T fluorometric assay and expressed as a percentage of the amount of amyloid incubated for the same time in the absence of the inhibitor. FIG. 17 shows the inhibition of A beta fibrillogenesis by iA beta containing all \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*. FIG. 18 shows the effect of iA beta on the promotion of A beta fibrillogenesis induced by apolipoprotein E. 30 mu g of A beta 1-40 were incubated with or without 2.4 mu g of human plasma apolipoprotein E (apoE). Samples of A beta alone or A beta / apoE were incubated also with 1:10 (A beta :iA beta) of the inhibitor. All the incubations were performed for 24 h at room temperature. Amyloid formation was evaluated by the thioflavine T fluorometric assay. The average of two different experiments is shown. FIG. 19 shows Alzheimer's amyloid plaque dissolution by iA beta. FIG. 20 shows the effect of iA beta on the A beta-induced cell toxicity. FIG. 21 shows the change in the conformation of the PrP 109-141 fragment as evaluated by circular dichroism at time points of 0, 1, 3, 5, 7 and 10 days. FIG. 22 shows samples of the PrP 109-141 fragment in a random coil or beta-sheet conformation being treated with proteinase K and electrophoresed on SDS polyacrylamide gel. Arrows on the left indicate the position of molecular weight standards. FIGS. 23A and 23B show the effect of the presence (FIG. 23B) or absence (FIG. 23A) of peptide iPrP-12aa on PrP109-141 fibrillogenesis as evaluated by electron microscopy. FIG. 24 shows the dose-dependent inhibition of PrP106-126 peptide fibrillogenesis by iPrP-12aa. The control peptide is CP1 (SEQ ID NO: 49). FIG. 25 shows the influence of iPrP-12aa on proteinase K degradation of PrP109-141 as determined by SDS-PAGE. Aliquots of PrP109-141 were converted from random coil to beta-sheet by incubation for 7 days under the conditions described in Example 2 for the circular dichroism study in the absence (lane 3) or in the presence of 10-fold molar excess of an unrelated control peptide (CP1) (lane 4) or iPrP-12aa (lane 5). The sample was then lyophilized and resuspended in PBS. A similar aliquot of the fragment that was not pre-incubated (adopting a random coil conformation) was also lyophilized and resuspended in PBS (lane 2). The samples were treated with proteinase K (1:400 w/w) for 60 min. The reactions were then stopped and the samples analyzed by electrophoresis as described above for the results shown in FIG. 22. Lane 1 corresponds to molecular weight standards. FIG. 26 shows the inhibition of PrP109-141 conformational transition with inhibitor peptide iPrP-12aa as evaluated by circular dichroism at t=0 and t=7 days. !

L5 ANSWER 220 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
AN 10269246 IFIPAT;IFIUDB;IFICDB  
TI PEPTIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER \*\*\*BETA\*\*\*  
- \*\*\*AMYLOID\*\*\* PROTEIN FIBRILLOGENESIS DISORDERS; ADMINISTERING  
LAMININ  
IN Castillo Gerardo; Snow Alan D  
PA Unassigned Or Assigned To Individual (68000)  
PI US 2003013648 A1 20030116  
AI US 2001-962955 20010924  
RLI US 1997-947057 19971008 CONTINUATION ABANDONED  
US 2001-938275 20010822 CONTINUATION-IN-PART PENDING  
PRAI US 1996-27981P 19961008 (Provisional)  
FI US 2003013648 20030116  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
OS CA 138:66664

GI

11 Figure(s).

FIG. 1 is a graph demonstrating an inhibitory effect of A \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* deposition into rodent hippocampus by laminin.  
FIG. 2 is a copy of a black and white photograph of a Coomassie blue  
stained gel demonstrating purification and isolation of fragments of  
laminin which strongly interact with A beta .  
FIG. 3 is a graph demonstrating the strong binding interaction of  
Alzheimer's A beta to the 55 kilodalton laminin fragment. A single  
dissociation constant with a  $K_d = 2.0 \times 10^{-9}$  was determined.  
FIG. 4 is a graph demonstrating the inhibition of Alzheimer's A beta  
fibril formation by selected fragments disclosed herein.  
FIG. 5 is a schematic representation of the sequence of human alpha-3  
chain globular domain peptides disclosed herein.  
FIG. 6 is a schematic representation of the sequence of murine alpha-4  
chain globular domain peptides disclosed herein.  
FIG. 7 is a schematic representation of the sequence of murine alpha-5  
chain globular domain peptides disclosed herein.  
FIG. 8 is a table which includes laminin globular domain-derived peptides  
which can disrupt/disassemble pre-formed Alzheimer's A beta 1-40 fibrils.  
FIG. 9 is a graph demonstrating further testing of selected laminin  
globular-domain derived peptides against pre-formed Alzheimer's A beta  
1-42 fibrils.  
FIG. 10 is a graph demonstrating dose-dependent disruption/ disassembly of  
pre-formed A beta 1-42 fibrils by laminin globular domain-derived  
peptides.  
FIG. 11 is a composite color photograph demonstrating amyloid enhancing  
effects of laminin-derived peptides.

L5

ANSWER 221 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN

AN

10189297 IFIPAT;IFIUDB;IFICDB

TI

THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN  
AMYLOIDGENIC DISEASE; COMPOUND FOR USE IN THE TREATMENT OF ALZHEIMER'S  
AND CREUZSFELDT-JACOB DISEASES

IN

Gefer Malcolm L; Gosselin Michael; Israel David I; Joyal John L

PA

Praecis Pharmaceuticals Inc (46269)

PI

US 2002133001 A1 20020919

AI

US 2001-996357 20011127

PRAI

US 2000-250198P 20001129 (Provisional)

US 2000-253302P 20001127 (Provisional)

US 2000-257186P 20001220 (Provisional)

FI

US 2002133001 20020919

DT

Utility; Patent Application - First Publication

FS

CHEMICAL  
APPLICATION

CLMN

78

GI

13 Figure(s).

FIG. 1 depicts a Western blot analysis of COS cell lysates and medium  
harvested from COS cells expressing the Fc region of mouse IgG1 fused to  
amino acid residues 1-40, 1-42, 10-25, 1630, 17-21, or 17-21 (A21L) of  
P-amyloid with or without an Nterminal triple glycine cap.  
FIG. 2 depicts an immunohistochemistry analysis of coronal brain sections  
from 20-22 week mice transgenic for both the Swedish mutation of  
\*\*\*amyloid\*\*\* \*\*\*precursor\*\*\* \*\*\*protein\*\*\* and presenilin of  
mouse IgG1 fused to various segments of P-amyloid, medium from  
nontransfected COS cells, or anti- \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
polyclonal antibody.  
FIG. 3 depicts the synthetic oligonucleotides that were used to assemble  
the synthetic APP/IgG gene. These oligonucleotides contain unique  
restriction endonuclease sites needed for the assembly.  
FIG. 4 is a schematic representation of the pTIg expression vector.  
FIG. 5 is a schematic representation of the assembly of synthetic A beta  
1-40 and A beta 1-42, with and without a triple Gly linker group between  
the tPA propeptide and the \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide.  
FIG. 6 depicts the DNA sequence, amino acid composition, and restriction  
endonuclease recognition sites of the synthetic \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* gene.  
FIG. 7A depicts the sequence of the oligonucleotides used to assemble  
subfragments of the synthetic \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* gene and a  
compilation of the chimeric \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* /IgG1  
constructs that were made.  
FIG. 7B depicts the sequence of the oligonucleotides used to assemble  
subfragments of the synthetic \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* gene and a  
compilation of the chimeric \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* /IgG1  
constructs that were made.  
FIG. 8 is a graph demonstrating that Fc receptor-mediated fibril uptake by

protein or the alpha- \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* antibody.  
 FIG. 9 is a graph demonstrating that the A beta (16-30)-Fc fusion protein interferes with the binding of soluble betaamyloid peptide to amyloid fibrils.  
 FIG. 10 is brain section stained with Thioflavin S, demonstrating that treatment of an Alzheimer's disease model transgenic mouse with the A beta (16-30)-Fc fusion protein results in a decrease in plaque at the site of administration.  
 FIG. 11 depicts the coding region of the tPA Delta pro/16-30/Fc cDNA synthetic gene (SEQ ID NO:11).  
 FIG. 12 depicts the amino acid sequence of the tPA Delta pro/1630/Fc fusion protein (SEQ ID NO:12). Annotated functional elements are also shown. The A beta (16-30)-Fc protein is set forth herein as SEQ ID NO: 13

L5 ANSWER 222 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 10159492 IFIPAT;IFIUDB;IFICDB  
 TI MODULATORS OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* PEPTIDE AGGREGATION  
 COMPRISING \*\*\*D\*\*\* - \*\*\*AMINO\*\*\* \*\*\*ACIDS\*\*\* ; AMINO-TERMINAL  
 MODIFYING GROUPS INCLUDE CYCLIC, HETEROCYCLIC, POLYCYCLIC AND BRANCHED  
 ALKYL, AND CARBOXY-TERMINAL MODIFYING GROUPS INCLUDE AN AMIDE, AN ALKYL  
 AMIDE, AN ARYL AMIDE OR A HYDROXY; TREATING ALZHEIMER'S DISEASE  
 IN Arico-Muendel Christopher C; Chin Joseph; Findeis Mark A; Gefter Malcolm  
 L; Hayward Neil J; Kelley Michael; Komar-Panicucci Sonja; Lee Jung-Ja;  
 Molineaux Susan; Musso Gary; Phillips Kathryn; Signer Ethan R; Wakefield  
 James  
 PA Praecis Pharmaceuticals Inc (46269)  
 PI US 2002103134 A1 20020801  
 AI US 2001-895443 20010629  
 RLI US 1997-920162 19970827 CONTINUATION GRANTED  
 US 1999-356931 19990719 CONTINUATION GRANTED  
 US 1995-548998 19951027 CONTINUATION-IN-PART ABANDONED  
 US 1996-616081 19960314 CONTINUATION-IN-PART ABANDONED  
 US 1996-703675 19960827 CONTINUATION-IN-PART GRANTED  
 US 1997-897342 19970721 CONTINUATION-IN-PART ABANDONED  
 FI US 2002103134 20020801  
 US 6689752 20040210  
 DT Utility; Patent Application - First Publication  
 FS CHEMICAL  
 APPLICATION  
 CLMN 16  
 GI 4 Figure(s).

FIG. 1 is a bar graph depicting the stability of an L-amino acidbased modulator compound (PPI-368) and two \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\*-based modulator compounds (PPI-433 and PPI-457) in cerebrospinal fluid.  
 FIG. 2 is a graph depicting the levels of PPI-558 in the plasma at 2, 8 and 24 hours following a single subcutaneous injection of PPI-558 (4.6 mg/kg) to male Sprague-Dawley rats. Each point is the mean +-standard error for four rats.  
 FIG. 3 is a graph depicting the levels of PPI-558 in the brain parenchyma (void of blood and brain capillaries) at 2, 8 and 24 hours following a single subcutaneous injection of PPI-558 (4.6 mg/kg) to male Sprague-Dawley rats. Each point is the mean +-standard error for four rats.  
 FIG. 4 is a graph depicting the ratio of brain parenchyma versus plasma levels of PPI-558 at 2, 8 and 24 hours following a single subcutaneous injection of PPI-558 (4.6 mg/kg) to male Sprague-Dawley rats. Each point is the mean +-standard error for four rats.

L5 ANSWER 223 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 03607375 IFIPAT;IFIUDB;IFICDB  
 TI MODULATORS OF AMYLOID AGGREGATION; AMYLOIDOGENIC PROTEIN, OR FRAGMENT THEREOF, MODIFIED WITH CIS-DECALIN GROUP, CHOLANOYL STRUCTURE, CHOLYL GROUP, DIETHYLENETRIAMINEPENTAACETYL GROUP, MENTHOXYACETYL GROUP, FLUORESCIEIN-CONTAINING GROUP, OR N-ACETYLNEURAMINYL GROUP  
 IN Benjamin Howard; Findeis Mark A; Garnick Marc B; Gefter Malcolm L; Hundal Arvind; Kasman Laura; Musso Gary; Reed Michael J; Signer Ethan R; Wakefield James  
 PA Praecis Pharmaceuticals Inc (46269)  
 PI US 6319498 B1 20011120  
 AI US 1996-617267 19960314  
 RLI US 1995-404831 19950314 CONTINUATION-IN-PART 5817626  
 US 1995-475579 19950607 CONTINUATION-IN-PART 5854215  
 US 1995-548998 19951027 CONTINUATION-IN-PART ABANDONED  
 FI US 6319498 20011120

US 5854215  
 DT Utility; CERTIFICATE OF CORRECTION  
 CDAT 15 Apr 2003  
 FS CHEMICAL  
 GRANTED  
 OS CA 135:376521  
 MRN 007985 MFN: 0785  
 007988 0534  
 008259 0771  
 008729 0818  
 CLMN 52  
 GI 4 Drawing Sheet(s), 9 Figure(s).

L5 ANSWER 224 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 03444263 IFIPAT;IFIUDB;IFICDB  
 TI TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY  
 \*\*\*BETA\*\*\* \*\*\*AMYLOID\*\*\* PEPTIDES; GENETIC ENGINEERED POLYPEPTIDE  
 IN Blanchard Barbara J; Ingram Vernon M  
 PA Massachusetts Institute of Technology (52912)  
 PI US 6172043 B1 20010109  
 AI US 1998-5215 19980109  
 RLI US 1997-960188 19971029 CONTINUATION-IN-PART ABANDONED  
 PRAI US 1997-35847P 19970110 (Provisional)  
 FI US 6172043 20010109  
 DT Utility; CERTIFICATE OF CORRECTION  
 CDAT 26 Feb 2002  
 FS CHEMICAL  
 GRANTED  
 OS CA 134:87979  
 MRN 009363 MFN: 0622  
 CLMN 18  
 GI 12 Drawing Sheet(s), 10 Figure(s).

L5 ANSWER 225 OF 367 JICST-Eplus COPYRIGHT 2004 JST on STN  
 AN 980168420 JICST-Eplus  
 TI Molecular biology of "Alzheimer disease". Racemization of . \*\*\*BETA\*\*\*  
 . \*\*\*amyloid\*\*\* protein. Roles of \*\*\*D\*\*\* - \*\*\*amino\*\*\*  
 \*\*\*acid\*\*\* contained . \*\*\*BETA\*\*\* . \*\*\*amyloid\*\*\* protein in  
 emergence of Alzheimer disease.  
 AU KANEKO ISAO  
 CS Sankyo Co., Ltd.  
 SO Brain Med, (1997) vol. 9, no. 4, pp. 375-381. Journal Code: L1063A (Fig.  
 5, Tbl. 1, Ref. 25)  
 ISSN: 0915-5759  
 CY Japan  
 DT Journal; General Review  
 LA Japanese  
 STA New

L5 ANSWER 226 OF 367 JICST-Eplus COPYRIGHT 2004 JST on STN  
 AN 960869136 JICST-Eplus  
 TI Roles of \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acid\*\*\* containing .  
 \*\*\*BETA\*\*\* . \*\*\*amyloid\*\*\* protein in Alzheimer disease crisis.  
 AU KANEKO ISAO; YAMADA NORIKO; KUBO TAKEKAZU; ODA TOMIICHIRO  
 CS Sankyo Co., Ltd.  
 SO Shinkei Kagaku (Bulletin of the Japanese Society for Neurochemistry),  
 (1996) vol. 35, no. 3, pp. 340-341. Journal Code: Y0225A (Fig. 2, Ref. 1)  
 ISSN: 0037-3796  
 CY Japan  
 DT Conference; Short Communication  
 LA Japanese  
 STA New

L5 ANSWER 227 OF 367 PROUSDDR COPYRIGHT 2004 PROUS SCIENCE on STN  
 AN 1998:5227 PROUSDDR  
 DN 264073  
 CN (3alpha,5beta,7alpha,12alpha)-Trihydroxycholesterol-24-oxy-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-L-alanine  
 CN DRUG NAME: PPI-368  
 RN 183746-33-0  
 MF C56 H83 N5 O10  
 HDP BIOLOGICAL TESTING  
 CO ORIGINATOR: Praecis  
 CC Cognition Disorders, Treatment of  
 OS SYNTHLINE 2000002537

STRUCTURE:

/ BINARY DATA / D-Amyloid I 8.30.04001.TIF

RTX RefID: 470169

ACTION - Low-molecular-weight peptido-organic compound that acts as a potent and selective inhibitor of \*\*\*amyloid\*\*\* -peptide (Abeta) polymerization and blocks the formation of all neurotoxic species of Abeta oligomers and fibril growth. Potentially useful as a lead for the development of therapeutic agents for the treatment of Alzheimer's disease.

PATENT REFERENCES:

TI Modulators of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide aggregation  
IN comprising \*\*\*D\*\*\* - \*\*\*amino\*\*\* \*\*\*acids\*\*\*  
Geffer, M.L.; Findeis, M.A.; Kelley, M.; Signer, E.R.; Musso, G.;  
Wakefield, J.; Molineaux, S.; Chin, J.; Lee, J.-J.; Komer-Panicucci, S.;  
Arico-Muendel, C.C.; Phillips, K.; Hayward, N.J.  
PA Praecis  
PI JP 2001500852 20010123  
WO 9808868 19980305  
PRAI US 1996-703675 19960827  
US 1997-897342 19970721

START LOCAL KERMIT RECEIVE PROCESS

BINARY DATA HAVE BEEN DOWNLOADED TO MULTIPLES FILES 'IMAGEennn.TIF'

L5 ANSWER 228 OF 367 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation,  
on STN

AN 97:229257 SCISEARCH

GA The Genuine Article (R) Number: WN147

TI All-D-enantiomers of \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* exhibit similar  
biological properties to all-L- \*\*\*beta\*\*\* - \*\*\*amyloids\*\*\*

AU Cribbs D H (Reprint); Pike C J; Weinstein S L; Velazquez P; Cotman C W

CS UNIV CALIF IRVINE, INST BRAIN AGING & DEMENTIA, DEPT PSYCHOBIOLOG, IRVINE,  
CA 92717 (Reprint); UNIV CALIF IRVINE, INST BRAIN AGING & DEMENTIA, DEPT  
NEUROL, IRVINE, CA 92717

CYA USA

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (14 MAR 1997) Vol. 272, No. 11, pp.  
7431-7436.

Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE  
PIKE, BETHESDA, MD 20814.

ISSN: 0021-9258.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 61

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 229 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN

AN 2003:153109 TOXCENTER

DN CRISP-2002-AG17787-02

TI Inhibitors of Alzheimer's Disease Amyloidosis

AU CASTILLO G M

CS CASTILLO@PROTEOTECH.COM, PROTEOTECH, INC, 12026 115TH AVE NE, KIRKLAND, WA  
98034 WASHINGTON

CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL  
INSTITUTES OF HEALTH, NATIONAL INSTITUTE ON AGING

SO Crisp Data Base National Institutes of Health.

DT (Research)

FS CRISP

LA English

ED Entered STN: 20030708

Last Updated on STN: 20030708

L5 ANSWER 230 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN

AN 2003:153013 TOXCENTER

DN CRISP-1997-AG00408-04

TI TOXICITY OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* IN ALZHEIMER'S DISEASE AND  
DOWN SYNDROME

CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL  
INSTITUTES OF HEALTH, NATIONAL INSTITUTE ON AGING  
SO Crisp Data Base National Institutes of Health.  
DT (Research)  
FS CRISP  
LA English  
ED Entered STN: 20030708  
Last Updated on STN: 20030708

L5 ANSWER 231 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN  
AN 2002:546351 TOXCENTER  
DN CRISP-98-G00408-04  
TI TOXICITY OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* IN ALZHEIMER'S DISEASE AND  
DOWN SYNDROME  
AU GALDZICKI Z  
CS NIA, NIH  
CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL  
INST. OF HEALTH, NATIONAL INSTITUTE ON AGING  
SO Crisp Data Base National Institutes Of Health.  
DT (Research)  
FS CRISP  
LA English  
ED Entered STN: 20021200  
Last Updated on STN: 20021200

L5 ANSWER 232 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN  
AN 2002:69105 TOXCENTER  
CP Copyright 2004 ACS  
TI Designed helical peptides as gamma-secreatase inhibitors  
AU Das, Chittaranjan; Wolfe, Michael S.; Tsai, Jui-Yi; Diehl, Thekla S.  
CS Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard  
Medical school, Boston, MA, 02115, USA.  
SO Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United  
States, April 7-11, 2002, (2002) pp. MEDI-011.  
CODEN: 69CKQP.  
CY UNITED STATES  
DT Conference  
FS CAPLUS  
OS CAPLUS 2002:190130  
LA English  
ED Entered STN: 20020319  
Last Updated on STN: 20020319

L5 ANSWER 233 OF 367 USPATFULL on STN  
AN 2004:211476 USPATFULL  
TI Polynucleotide encoding neuromedin U receptor  
IN Harland, Lee, Kent, UNITED KINGDOM  
PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6780611 B1 20040824  
AI US 2000-684725 20001006 (9)  
PRAI GB 1999-23888 19991008  
DT Utility  
FS GRANTED  
LN.CNT 3220  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500  
IC [7]  
ICM: C12N015-00  
ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04  
EXF 536/23.5; 536/23.1; 536/24.3; 435/320.1; 435/325; 435/252.3; 435/254.11;  
435/254.2; 435/69.1; 435/254.1; 435/455

L5 ANSWER 234 OF 367 USPATFULL on STN  
AN 2004:203889 USPATFULL  
TI Peptide binding the KLVFF-sequence of \*\*\*amyloid\*\*\* - \*\*\*beta\*\*\*  
IN Nordstedt, Christer, Mulhouse, FRANCE  
Naslund, Jan, Stockholm, SWEDEN  
Thyberg, Johan, Stockholm, SWEDEN  
Tjernberg, Lars O., Spanga, SWEDEN  
Terenius, Lars, Uppsala, SWEDEN  
PA Karolinska Innovations AB, Stockholm, SWEDEN (non-U.S. corporation)  
PI US 2004157781 A1 20040812  
AI US 2003-721774 A1 20031126 (10)

Division of Ser. No. US 1998-95106, filed on 10 Jun 1998, GRANTED, Pat.  
No. US 6331440 Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec  
1996, UNKNOWN

PRAI SE 1995-4467 19951212  
US 1995-9386P 19951229 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 724  
INCL INCLM: 514/016.000  
INCLS: 530/329.000  
NCL NCLM: 514/016.000  
NCLS: 530/329.000  
IC [7]  
ICM: A61K038-08  
ICS: C07K007-06

L5 ANSWER 235 OF 367 USPATFULL on STN

AN 2004:202975 USPATFULL

TI Immunogenic HBC chimera particles having enhanced stability

IN Birkett, Ashley J., Escondido, CA, UNITED STATES

PI US 2004156864 A1 20040812

AI US 2004-805913 A1 20040322 (10)

RLI Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001,  
PENDING

PRAI WO 2001-US41759 20010816  
US 2000-226867P 20000822 (60)  
US 2000-225843P 20000816 (60)

DT Utility  
FS APPLICATION

LN.CNT 7005

INCL INCLM: 424/189.100

INCLS: 530/350.000

NCL NCLM: 424/189.100

NCLS: 530/350.000

IC [7]  
ICM: A61K039-29  
ICS: C12P021-04; C07K014-02

L5 ANSWER 236 OF 367 USPATFULL on STN

AN 2004:202974 USPATFULL

TI Stabilized HBC chimera particles as therapeutic vaccine for chronic  
hepatitis

IN Page, Mark, Allestree, UNITED KINGDOM

Friede, Martin, Cergue, SWITZERLAND

Schmidt, Annette Elisabeth, Planegg, GERMANY, FEDERAL REPUBLIC OF

Stober, Detlef, Muenchen, GERMANY, FEDERAL REPUBLIC OF

PI US 2004156863 A1 20040812

AI US 2003-677074 A1 20031001 (10)

RLI Continuation-in-part of Ser. No. US 2003-372076, filed on 21 Feb 2003,  
PENDING Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb  
2002, ABANDONED Continuation-in-part of Ser. No. US 2002-80299, filed on  
21 Feb 2002, PENDING

DT Utility  
FS APPLICATION

LN.CNT 5846

INCL INCLM: 424/189.100

NCL NCLM: 424/189.100

IC [7]  
ICM: A61K039-29

L5 ANSWER 237 OF 367 USPATFULL on STN

AN 2004:197569 USPATFULL

TI Immunogenic HBC chimera particles having enhanced stability

IN Birkett, Ashley J., Escondido, CA, UNITED STATES

PI US 2004152876 A1 20040805

AI US 2004-806006 A1 20040322 (10)

RLI Division of Ser. No. US 2001-930915, filed on 15 Aug 2001, PENDING

PRAI WO 2001-US41759 20010816  
US 2000-226867P 20000822 (60)  
US 2000-225843P 20000816 (60)

DT Utility  
FS APPLICATION

LN.CNT 7068

INCL INCLM: 530/350.000

NCL NCLM: 530/350.000



ICM: C07K014-005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 238 OF 367 USPATFULL on STN  
AN 2004:189756 USPATFULL  
TI Stabilized immunogenic HBC chimer particles  
IN Lyons, Katelynne, Carlsbad, CA, UNITED STATES  
Birkett, Ashley J., Escondido, CA, UNITED STATES  
Haron, Jay A., Jamul, CA, UNITED STATES  
PI US 2004146524 A1 20040729  
AI US 2003-732862 A1 20031210 (10)  
RLI Continuation-in-part of Ser. No. US 2002-274616, filed on 21 Oct 2002,  
PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb  
2002, PENDING Continuation-in-part of Ser. No. US 2002-82014, filed on  
21 Feb 2002, PENDING  
PRAI US 2002-432123P 20021210 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8390  
INCL INCLM: 424/189.100  
INCLS: 530/350.000  
NCL NCLM: 424/189.100  
NCLS: 530/350.000  
IC [7]  
ICM: A61K039-29  
ICS: C07K014-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 239 OF 367 USPATFULL on STN  
AN 2004:178983 USPATFULL  
TI Treatment of neurodegenerative diseases using proteasome modulators  
IN Ramesh, Tennore, Dublin, OH, UNITED STATES  
Scott, Sean, San Francisco, CA, UNITED STATES  
PA ALS Therapy Development Foundation (U.S. corporation)  
PI US 2004138153 A1 20040715  
AI US 2003-453912 A1 20030603 (10)  
PRAI US 2002-385489P 20020603 (60)  
US 2002-385625P 20020603 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2167  
INCL INCLM: 514/043.000  
INCLS: 514/220.000  
NCL NCLM: 514/043.000  
NCLS: 514/220.000  
IC [7]  
ICM: A61K031-7056  
ICS: A61K031-551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 240 OF 367 USPATFULL on STN  
AN 2004:174261 USPATFULL  
TI Passive immunization treatment of Alzheimer's disease  
IN Schenk, Dale B., Burlingame, CA, United States  
PA Neuralab Limited, BERMUDA (non-U.S. corporation)  
PI US 6761888 B1 20040713  
AI US 2000-580018 20000526 (9)  
DT Utility  
FS GRANTED  
LN.CNT 5303  
INCL INCLM: 424/130.100  
INCLS: 530/300.000; 530/350.000; 530/387.100  
NCL NCLM: 424/130.100  
NCLS: 530/300.000; 530/350.000; 530/387.100  
IC [7]  
ICM: C07K016-00  
ICS: C07K016-18; A61K039-00  
EXF 530/300; 530/350; 530/387.1; 424/130.1; 424/131.1; 424/141.1; 424/141.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 241 OF 367 USPATFULL on STN  
AN 2004:160529 USPATFULL  
TI Methods of treating neurodegenerative diseases  
IN Lu, Kun Ping, Newton, MA, UNITED STATES  
Hunter, Tony R., Del Mar, CA, UNITED STATES

PA BETH ISRAEL DEACONESS MEDICAL CENTER, Boston, MA (U.S. corporation)  
The Salk Institute for Biological Studies, La Jolla, CA (U.S.  
corporation)  
PI US 2004123334 A1 20040624  
AI US 2004-641815 A1 20040112 (10)  
PRAI US 2002-404030P 20020815 (60)  
US 2003-469546P 20030508 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1932  
INCL INCLM: 800/003.000  
INCLS: 424/009.200; 800/012.000  
NCL NCLM: 800/003.000  
NCLS: 424/009.200; 800/012.000  
IC [7]  
ICM: A01K067-00  
ICS: A61K049-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 242 OF 367 USPATFULL on STN  
AN 2004:146997 USPATFULL  
TI Humanized and chimeric N-terminal \*\*\*amyloid\*\*\* \*\*\*beta\*\*\*  
-antibodies  
IN Schenk, Dale B., Burlingame, CA, United States  
Bard, Frederique, Pacifica, CA, United States  
Yednock, Theodore, Forest Knolls, CA, United States  
PA Neuralab Limited, BERMUDA (non-U.S. corporation)  
PI US 6750324 B1 20040615  
AI US 2000-724552 20001128 (9)  
RLI Continuation of Ser. No. US 2000-580018, filed on 26 May 2000  
Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999  
Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998  
PRAI US 1998-80970P 19980407 (60)  
US 1997-67740P 19971202 (60)  
DT Utility  
FS GRANTED  
LN.CNT 5272  
INCL INCLM: 530/387.100  
INCLS: 530/300.000; 530/350.000; 424/130.100  
NCL NCLM: 530/387.100  
NCLS: 424/130.100; 530/300.000; 530/350.000  
IC [7]  
ICM: C07K016-00  
ICS: C07K016-18; A61K039-00  
EXF 530/300; 530/350; 530/387.1; 424/130.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 243 OF 367 USPATFULL on STN  
AN 2004:135611 USPATFULL  
TI Prevention and treatment of amyloidogenic disease  
IN Schenk, Dale B., Burlingame, CA, United States  
PA Neuralab Limited, BERMUDA (non-U.S. corporation)  
PI US 6743427 B1 20040601  
AI US 2000-724961 20001128 (9)  
RLI Continuation of Ser. No. US 2000-580015, filed on 26 May 2000  
Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999  
Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998  
PRAI US 1998-80970P 19980407 (60)  
US 1997-67740P 19971202 (60)  
DT Utility  
FS GRANTED  
LN.CNT 5449  
INCL INCLM: 424/130.100  
INCLS: 530/300.000; 530/350.000; 530/387.100  
NCL NCLM: 424/130.100  
NCLS: 530/300.000; 530/350.000; 530/387.100  
IC [7]  
ICM: C07K016-00  
ICS: C07K016-18; A61K039-00  
EXF 530/300; 530/350; 530/387.1; 724/130.1; 724/133.1; 724/139.1; 724/141;  
724/142.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 244 OF 367 USPATFULL on STN  
AN 2004:114174 USPATFULL

peptides and uses therefor  
IN Holmes, Todd, Belmont, MA, UNITED STATES  
Zhang, Shuguang, Lexington, MA, UNITED STATES  
Rich, Alexander, Cambridge, MA, UNITED STATES  
DiPersio, C. Michael, Norton, MA, UNITED STATES  
Lockshin, Curtis, Lexington, MA, UNITED STATES  
PI US 2004087013 A1 20040506  
AI US 2003-390472 A1 20030317 (10)  
RLI Continuation of Ser. No. US 1997-824515, filed on 26 Mar 1997, GRANTED,  
Pat. No. US 5987623 Continuation of Ser. No. US 1994-293284, filed on 22  
Aug 1994, GRANTED, Pat. No. US 5955343 Continuation-in-part of Ser. No.  
US 1992-973326, filed on 28 Dec 1992, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 2512  
INCL INCLM: 435/325.000  
INCLS: 530/329.000  
NCL NCLM: 435/325.000  
NCLS: 530/329.000  
IC [7]  
ICM: C12N005-02  
ICS: C07K007-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 245 OF 367 USPATFULL on STN  
AN 2004:114052 USPATFULL  
TI Dehydrogenase oligomeric modulators  
IN Tatton, William G., Yorktown Heights, NY, UNITED STATES  
Borden, Katherine, New Rochelle, NY, UNITED STATES  
PI US 2004086891 A1 20040506  
AI US 2003-414809 A1 20030416 (10)  
RLI Continuation of Ser. No. US 1999-327200, filed on 7 Jun 1999, ABANDONED  
PRAI US 1998-88771P 19980610 (60)  
US 1998-92054P 19980708 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1546  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]  
ICM: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 246 OF 367 USPATFULL on STN  
AN 2004:113677 USPATFULL  
TI Methods  
IN Foxwell, Brian Maurice John, London, UNITED KINGDOM  
Feldmann, Marc, London, UNITED KINGDOM  
PI US 2004086516 A1 20040506  
AI US 2003-450786 A1 20031010 (10)  
WO 2001-GB5724 20011221  
PRAI GB 2000-31454 20001222  
GB 2001-27625 20011117  
DT Utility  
FS APPLICATION  
LN.CNT 2822  
INCL INCLM: 424/184.100  
NCL NCLM: 424/184.100  
IC [7]  
ICM: A61K039-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 247 OF 367 USPATFULL on STN  
AN 2004:107249 USPATFULL  
TI Adzymes and uses thereof  
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES  
Lee, Frank D., Chestnut Hill, MA, UNITED STATES  
Wong, Gordon G., Brookline, MA, UNITED STATES  
Das Gupta, Ruchira, Auburndale, MA, UNITED STATES  
Baynes, Brian, Somerville, MA, UNITED STATES  
PI US 2004081648 A1 20040429  
AI US 2003-650592 A1 20030827 (10)  
PRAI US 2002-406517P 20020827 (60)  
US 2002-423754P 20021105 (60)  
US 2002-430001P 20021127 (60)

FS APPLICATION  
LN.CNT 8325  
INCL INCLM: 424/094.630  
INCLS: 435/226.000  
NCL NCLM: 424/094.630  
NCLS: 435/226.000  
IC [7]  
ICM: A61K038-48  
ICS: C12N009-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 248 OF 367 USPATFULL on STN  
AN 2004:107248 USPATFULL  
TI Adzymes and uses thereof  
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES  
Lee, Frank D., Chestnut Hill, MA, UNITED STATES  
Wong, Gordon G., Brookline, MA, UNITED STATES  
DasGupta, Ruchira, Auburndale, MA, UNITED STATES  
Baynes, Brian, Somerville, MA, UNITED STATES  
PI US 2004081647 A1 20040429  
AI US 2003-650591 A1 20030827 (10)  
PRAI US 2002-406517P 20020827 (60)  
US 2002-423754P 20021105 (60)  
US 2002-430001P 20021127 (60)

DT Utility  
FS APPLICATION  
LN.CNT 7919  
INCL INCLM: 424/094.630  
INCLS: 435/069.700; 435/226.000  
NCL NCLM: 424/094.630  
NCLS: 435/069.700; 435/226.000  
IC [7]  
ICM: A61K038-48  
ICS: C12N009-64; C12P021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 249 OF 367 USPATFULL on STN  
AN 2004:88231 USPATFULL  
TI Macrocyclic chelants for metallopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2004067200 A1 20040408  
AI US 2003-663090 A1 20030915 (10)  
RLI Division of Ser. No. US 2000-660377, filed on 12 Sep 2000, GRANTED, Pat.  
No. US 6685914  
PRAI US 1999-153512P 19990913 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2942  
INCL INCLM: 424/009.363  
INCLS: 540/465.000; 540/474.000  
NCL NCLM: 424/009.363  
NCLS: 540/465.000; 540/474.000  
IC [7]  
ICM: A61K049-00  
ICS: C07F005-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 250 OF 367 USPATFULL on STN  
AN 2004:77121 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting beta-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James A., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES

Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2004058900 A1 20040325  
AI US 2003-336767 A1 20030106 (10)  
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING  
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25655  
INCL INCLM: 514/183.000  
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;  
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000  
NCL NCLM: 514/183.000  
NCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;  
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000  
IC [7]  
ICM: A61K031-553  
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 251 OF 367 USPATFULL on STN  
AN 2004:77072 USPATFULL  
TI Specific autoimmune reactions against isomerised/optically inverted  
epitopes: application for diagnosis of autoimmune diseases  
IN Cloos, Paul, Kobenhavn, DENMARK  
Christgau, Stephan, Gentofte, DENMARK  
PI US 2004058851 A1 20040325  
AI US 2002-75372 A1 20020215 (10)  
RLI Continuation of Ser. No. WO 2000-EP7973, filed on 16 Aug 2000, UNKNOWN  
PRAI GB 1999-19452 19990817  
DT Utility  
FS APPLICATION  
LN.CNT 1711  
INCL INCLM: 514/002.000  
INCLS: 435/007.210  
NCL NCLM: 514/002.000  
NCLS: 435/007.210  
IC [7]  
ICM: G01N033-567  
ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 252 OF 367 USPATFULL on STN  
AN 2004:70761 USPATFULL  
TI Dithiolthione compounds for the treatment of neurological disorders and  
for memory enhancement  
IN Prendergast, Patrick T., Straffan, IRELAND  
Armstrong, Paul, Belfast, UNITED KINGDOM  
PA Patrick Prendergast, Straffan, IRELAND (non-U.S. corporation)  
PI US 2004053989 A1 20040318  
AI US 2003-612476 A1 20030702 (10)  
RLI Continuation of Ser. No. US 2000-627641, filed on 28 Jul 2000, ABANDONED  
PRAI IE 2000-20000302 20000413  
IE 2000-20000304 20000413  
US 1999-145964P 19990729 (60)  
US 2000-198338P 20000418 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4051  
INCL INCLM: 514/440.000  
INCLS: 514/210.190; 514/217.030; 514/326.000; 514/422.000  
NCL NCLM: 514/440.000  
NCLS: 514/210.190; 514/217.030; 514/326.000; 514/422.000  
IC [7]  
ICM: A61K031-385  
ICS: A61K031-55; A61K031-453; A61K031-4025  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 253 OF 367 USPATFULL on STN

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James E., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2004043977 A1 20040304  
 AI US 2003-336687 A1 20030106 (10)  
 RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat. No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 25738  
 INCL INCLM: 514/183.000  
 INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000  
 NCL NCLM: 514/183.000  
 NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000  
 IC [7]  
 ICM: A61K031-5513  
 ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445; A61K031-366; A61K031-137  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 254 OF 367 USPATFULL on STN  
 AN 2004:51633 USPATFULL  
 TI Amine 1,2- and 1,3-diol compounds  
 IN Romero, Arthur G., Kalamazoo, MI, UNITED STATES  
 Schostarez, Heinrich J., Portage, MI, UNITED STATES  
 Roels, Christina M., Battle Creek, MI, UNITED STATES  
 PI US 2004039064 A1 20040226  
 AI US 2002-299739 A1 20021119 (10)  
 PRAI US 2001-333081P 20011119 (60)  
 US 2001-334000P 20011128 (60)  
 US 2002-362752P 20020308 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 10130  
 INCL INCLM: 514/651.000  
 INCLS: 564/355.000  
 NCL NCLM: 514/651.000  
 NCLS: 564/355.000  
 IC [7]  
 ICM: A61K031-137  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 255 OF 367 USPATFULL on STN  
 AN 2004:51445 USPATFULL

IN Pepinsky, R. Blake, Arlington, MA, UNITED STATES  
Taylor, Frederick R., Milton, MA, UNITED STATES  
Garber, Ellen A., Cambridge, MA, UNITED STATES  
PI US 2004038876 A1 20040226  
AI US 2002-244095 A1 20020912 (10)  
RLI Continuation of Ser. No. US 979752, ABANDONED A 371 of International  
Ser. No. WO 2000-US14741, filed on 26 May 2000, PENDING  
PRAI US 1999-137011P 19990601 (60)  
US 1999-149016P 19990813 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4595  
INCL INCLM: 514/012.000  
INCLS: 530/350.000  
NCL NCLM: 514/012.000  
NCLS: 530/350.000  
IC [7]  
ICM: A61K038-17  
ICS: C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 256 OF 367 USPATFULL on STN  
AN 2004:38077 USPATFULL  
TI Dopamine agonist formulations for enhanced central nervous system  
delivery  
IN Quay, Steven C., Edmonds, WA, UNITED STATES  
PA Natestch Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)  
PI US 2004028613 A1 20040212  
AI US 2001-891630 A1 20010625 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 8045  
INCL INCLM: 424/045.000  
INCLS: 514/295.000  
NCL NCLM: 424/045.000  
NCLS: 514/295.000  
IC [7]  
ICM: A61K031-473  
ICS: A61L009-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 257 OF 367 USPATFULL on STN  
AN 2004:31067 USPATFULL  
TI Method of recovering a nucleic acid encoding a proteinaceous binding  
domain which binds a target material  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2004023205 A1 20040205  
AI US 2002-126544 A1 20020422 (10)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15868  
INCL INCLM: 435/005.000  
INCLS: 435/006.000; 536/023.100; 536/023.720  
NCL NCLM: 435/005.000  
NCLS: 435/006.000; 536/023.100; 536/023.720  
IC [7]  
ICM: C12Q001-70  
ICS: C12Q001-68; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 258 OF 367 USPATFULL on STN

TI      Macrocyclic chelants for metallopharmaceuticals  
IN      Liu, Shuang, Chelmsford, MA, United States  
PA      Bristol-Myers Squibb Pharma Company, Princeton, NJ, United States (U.S.  
          corporation)  
PI      US 6685914                    B1      20040203  
AI      US 2000-660377                20000912 (9)  
PRAI    US 1999-153512P            19990913 (60)  
DT      Utility  
FS      GRANTED  
LN.CNT  2889  
INCL    INCLM: 424/009.300  
          INCLS: 424/001.110; 424/009.100; 424/001.650; 540/465.000; 534/010.000;  
                  534/014.000  
NCL      NCLM: 424/009.300  
          NCLS: 424/001.110; 424/001.650; 424/009.100; 534/010.000; 534/014.000;  
                  540/465.000  
IC      [7]  
          ICM: A61B049-00  
EXF      424/1.11; 424/1.65; 424/9.1; 424/9.3; 424/9.4; 424/9.5; 424/9.6;  
          424/9.7; 424/9.8; 534/7; 534/10-16; 540/450; 540/465  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5      ANSWER 259 OF 367   USPATFULL on STN  
AN      2004:24723   USPATFULL  
TI      Receptor detection  
IN      Rouhani, Riaz, Concord, CA, UNITED STATES  
          Naqvi, Tabassum, Fremont, CA, UNITED STATES  
          Singh, Rajendra, San Jose, CA, UNITED STATES  
PI      US 2004018562            A1      20040129  
AI      US 2003-448609            A1      20030529 (10)  
PRAI    US 2002-384060P            20020529 (60)  
DT      Utility  
FS      APPLICATION  
LN.CNT  918  
INCL    INCLM: 435/007.100  
          INCLS: 435/007.200  
NCL      NCLM: 435/007.100  
          NCLS: 435/007.200  
IC      [7]  
          ICM: G01N033-53  
          ICS: G01N033-567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5      ANSWER 260 OF 367   USPATFULL on STN  
AN      2004:7420   USPATFULL  
TI      Method of producing polyvalent antigens  
IN      Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES  
PI      US 2004005654            A1      20040108  
AI      US 2002-231114            A1      20020828 (10)  
PRAI    US 2002-361166P            20020301 (60)  
          US 2002-363445P            20020308 (60)  
DT      Utility  
FS      APPLICATION  
LN.CNT  3452  
INCL    INCLM: 435/068.100  
          INCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000;  
                  424/085.100; 424/185.100; 424/234.100; 424/204.100  
NCL      NCLM: 435/068.100  
          NCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000;  
                  424/085.100; 424/185.100; 424/234.100; 424/204.100  
IC      [7]  
          ICM: C12P021-06  
          ICS: A61K039-00; A61K039-12; A61K039-02; C12N007-00; C12N001-20;  
          C07K014-52; C07K014-715; C07K014-02; C07K014-195  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5      ANSWER 261 OF 367   USPATFULL on STN  
AN      2004:7306   USPATFULL  
TI      Nucleic acids, genetic constructs, and library of nucleic acids encoding  
          fusion proteins  
IN      Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
          Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
          Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
          Markland, William, Milford, MA, UNITED STATES  
          Ley, Arthur Charles, Newton, MA, UNITED STATES



PI US 2004005539 A1 20040108  
AI US 2002-127028 A1 20020422 (10)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 16057  
INCL INCLM: 435/005.000  
INCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;  
435/320.100; 536/023.720  
NCL NCLM: 435/005.000  
NCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;  
435/320.100; 536/023.720  
IC [7]  
ICM: C12Q001-70  
ICS: C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N001-21;  
C12N015-86  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 262 OF 367 USPATFULL on STN  
AN 2004:7074 USPATFULL  
TI Modulators of amyloid aggregation  
IN Findeis, Mark A., Cambridge, MA, UNITED STATES  
Benjamin, Howard, Lexington, MA, UNITED STATES  
Garnick, Marc B., Brookline, MA, UNITED STATES  
Gefter, Malcolm L., Lincoln, MA, UNITED STATES  
Hundal, Arvind, Brighton, MA, UNITED STATES  
Kasman, Laura, Athens, GA, UNITED STATES  
Musso, Gary, Hopkinton, MA, UNITED STATES  
Signer, Ethan R., Cambridge, MA, UNITED STATES  
Wakefield, James, Brookline, MA, UNITED STATES  
Reed, Michael J., Marietta, GA, UNITED STATES  
PA Praecis Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)  
PI US 2004005307 A1 20040108  
AI US 2003-463729 A1 20030617 (10)  
RLI Continuation of Ser. No. US 2001-972475, filed on 4 Oct 2001, PENDING  
Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, GRANTED,  
Pat. No. US 6319498 Continuation-in-part of Ser. No. US 1995-404831,  
filed on 14 Mar 1995, GRANTED, Pat. No. US 5817626 Continuation-in-part  
of Ser. No. US 1995-475579, filed on 7 Jun 1995, GRANTED, Pat. No. US  
5854215 Continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct  
1995, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4197  
INCL INCLM: 424/094.300  
INCLS: 514/012.000  
NCL NCLM: 424/094.300  
NCLS: 514/012.000  
IC [7]  
ICM: A61K038-54  
ICS: A61K038-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 263 OF 367 USPATFULL on STN  
AN 2004:1829 USPATFULL  
TI Method of producing disease-specific antigens  
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES  
PI US 2004001848 A1 20040101  
AI US 2002-231213 A1 20020828 (10)  
PRAI US 2002-361166P 20020301 (60)  
US 2002-363445P 20020308 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3423  
INCL INCLM: 424/186.100  
INCLS: 424/185.100; 424/191.100; 424/190.100; 435/069.300  
NCL NCLM: 424/186.100

IC [7]  
 ICM: A61K039-00  
 ICS: A61K039-12; A61K039-02; A61K039-002; C12P021-02  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 264 OF 367 USPATFULL on STN  
 AN 2003:329844 USPATFULL  
 TI Innate immune system-directed vaccines  
 IN Medzhitov, Ruslan, New Haven, CT, UNITED STATES  
 PI US 2003232055 A1 20031218  
 AI US 2003-353316 A1 20030129 (10)  
 RLI Continuation of Ser. No. WO 2001-US24228, filed on 31 Jul 2001, PENDING  
 PRAI US 2000-258329P 20001228 (60)  
 US 2001-282604P 20010409 (60)  
 US 2000-222042P 20000731 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3106  
 INCL INCLM: 424/185.100  
 INCLS: 424/186.100; 424/190.100; 424/191.100; 530/350.000; 530/359.000;  
 530/395.000  
 NCL NCLM: 424/185.100  
 NCLS: 424/186.100; 424/190.100; 424/191.100; 530/350.000; 530/359.000;  
 530/395.000

IC [7]  
 ICM: A61K039-00  
 ICS: A61K039-12; A61K039-02; A61K039-002; C07K014-02; C07K014-195;  
 C07K014-435; C07K014-775  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 265 OF 367 USPATFULL on STN  
 AN 2003:318732 USPATFULL  
 TI Method of producing transglutaminase reactive compound  
 IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES  
 PI US 2003224476 A1 20031204  
 AI US 2002-231063 A1 20020828 (10)  
 PRAI US 2002-361166P 20020301 (60)  
 US 2002-363445P 20020308 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3307  
 INCL INCLM: 435/068.100  
 INCLS: 530/350.000; 530/351.000; 530/395.000; 435/235.100  
 NCL NCLM: 435/068.100  
 NCLS: 530/350.000; 530/351.000; 530/395.000; 435/235.100

IC [7]  
 ICM: C12P021-06  
 ICS: C12N007-00; C07K014-52; C07K014-435; C07K014-02; C07K014-195  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 266 OF 367 USPATFULL on STN  
 AN 2003:312289 USPATFULL  
 TI Directed evolution of novel binding proteins  
 IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
 Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
 Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
 Markland, William, Milford, MA, UNITED STATES  
 Ley, Arthur Charles, Newton, MA, UNITED STATES  
 Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
 PI US 2003219886 A1 20031127  
 AI US 2001-896095 A1 20010629 (9)  
 RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING  
 Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
 Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
 ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
 Sep 1988, ABANDONED  
 PRAI WO 1989-US3731 19890901  
 DT Utility  
 FS APPLICATION  
 LN.CNT 15529  
 INCL INCLM: 435/184.000  
 INCLS: 435/007.100

IC NCLS: 435/007.100  
[7]  
ICM: C12N009-99  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 267 OF 367 USPATFULL on STN  
AN 2003:312260 USPATFULL  
TI Method of producing transglutaminase having broad substrate activity  
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES  
PI US 2003219857 A1 20031127  
AI US 2002-231470 A1 20020828 (10)  
PRAI US 2002-361166P 20020301 (60)  
US 2002-363445P 20020308 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3442  
INCL INCLM: 435/069.100  
INCLS: 435/193.000; 435/320.100; 435/325.000; 435/252.300; 536/023.200  
NCL NCLM: 435/069.100  
NCLS: 435/193.000; 435/320.100; 435/325.000; 435/252.300; 536/023.200  
IC [7]  
ICM: C12P021-02  
ICS: C07H021-04; C12N009-10; C12N001-21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 268 OF 367 USPATFULL on STN  
AN 2003:312256 USPATFULL  
TI Method of cross-linking a compound  
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES  
PI US 2003219853 A1 20031127  
AI US 2002-231298 A1 20020828 (10)  
PRAI US 2002-361166P 20020301 (60)  
US 2002-363445P 20020308 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3367  
INCL INCLM: 435/068.100  
INCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000  
NCL NCLM: 435/068.100  
NCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000  
IC [7]  
ICM: C12P021-06  
ICS: C12N007-00; C12N001-20; C07K014-52; C07K014-715; C07K014-195;  
C07K014-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 269 OF 367 USPATFULL on STN  
AN 2003:312125 USPATFULL  
TI Fusion proteins, modified filamentous bacteriophage, and populations or  
libraries of same  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2003219722 A1 20031127  
AI US 2002-126685 A1 20020422 (10)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 16459  
INCL INCLM: 435/005.000  
INCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720  
NCL NCLM: 435/005.000  
NCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720  
IC [7]

ICS: C12Q001-70; C07H021-04; C12P021-04; C12N001-21; C12N015-74  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 270 OF 367 USPATFULL on STN  
AN 2003:306883 USPATFULL  
TI Specific autoimmune reactions against isomerised/optically inverted  
epitopes: application for treatment of autoimmune diseases  
IN Cloos, Paul A.C., Kobenhavn, DENMARK  
Christgau, Stephan, Gentofte, DENMARK  
PI US 2003216319 A1 20031120  
AI US 2003-367571 A1 20030214 (10)  
RLI Continuation of Ser. No. WO 2001-EP9205, filed on 9 Aug 2001, UNKNOWN  
PRAI GB 2000-20238 20000816  
DT Utility  
FS APPLICATION  
LN.CNT 2516  
INCL INCLM: 514/013.000  
INCLS: 514/014.000; 514/015.000; 514/016.000  
NCL NCLM: 514/013.000  
NCLS: 514/014.000; 514/015.000; 514/016.000  
IC [7]  
ICM: A61K038-10  
ICS: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 271 OF 367 USPATFULL on STN  
AN 2003:282304 USPATFULL  
TI Stabilized Hbc chimera particles as therapeutic vaccine for chronic  
hepatitis  
IN Page, Mark, Allestree, UNITED KINGDOM  
Friede, Martin, Cardiff, CA, UNITED STATES  
PI US 2003198645 A1 20031023  
AI US 2003-372076 A1 20030221 (10)  
RLI Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb 2002,  
PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb  
2002, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 5638  
INCL INCLM: 424/192.100  
INCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700  
NCL NCLM: 424/192.100  
NCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700  
IC [7]  
ICM: C07H021-04  
ICS: A61K039-29; A61K039-00; A61K039-002; C07K001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 272 OF 367 USPATFULL on STN  
AN 2003:279186 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting .beta.-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Pleiss, Michael A., Sunnyvale, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Neitz, R. Jeffrey, San Francisco, CA, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Freedman, Stephen, Walnut Creek, CA, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James A., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Henry, Steven S., New Palestine, IN, United States  
McDaniel, Stacey L., Indianapolis, IN, United States  
Scott, William Leonard, Indianapolis, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6635632 B1 20031021  
AI US 1997-996422 19971222 (8)  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS GRANTED  
LN.CNT 22179  
INCL INCLM: 514/212.030  
INCLS: 514/212.040; 514/212.070; 514/212.080  
NCL NCLM: 514/212.030  
NCLS: 514/212.040; 514/212.070; 514/212.080  
IC [7]  
ICM: A61K031-55  
ICS: A61P025-28  
EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 273 OF 367 USPATFULL on STN  
AN 2003:265929 USPATFULL  
TI Suppression of cytotoxic protein conformers  
IN Cooper, Garth James Smith, Auckland, NEW ZEALAND  
Loomes, Kerry Martin, Auckland, NEW ZEALAND  
Aitken, Jacqueline Fiona, Auckland, NEW ZEALAND  
PI US 2003186946 A1 20031002  
AI US 2003-354893 A1 20030129 (10)  
PRAI NZ 2002-516920 20020129  
DT Utility  
FS APPLICATION  
LN.CNT 2367  
INCL INCLM: 514/150.000  
INCLS: 514/228.200; 514/297.000; 514/280.000; 514/152.000; 514/765.000  
NCL NCLM: 514/150.000  
NCLS: 514/228.200; 514/297.000; 514/280.000; 514/152.000; 514/765.000  
IC [7]  
ICM: A61K031-655  
ICS: A61K031-65; A61K031-542; A61K031-4745; A61K031-473; A61K031-015  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 274 OF 367 USPATFULL on STN  
AN 2003:264844 USPATFULL  
TI Immunogenic HBC chimera particles stabilized with an N-terminal cysteine  
IN Birkett, Ashley J., Escondido, CA, UNITED STATES  
PI US 2003185858 A1 20031002  
AI US 2002-82014 A1 20020221 (10)  
RLI Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001,  
PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 5511  
INCL INCLM: 424/227.100  
INCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720  
NCL NCLM: 424/227.100  
NCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720  
IC [7]  
ICM: C07H021-04  
ICS: A61K039-002; A61K045-00; C12N015-00; C12N015-63; C12N015-74;  
C07K014-00; A61K039-00; A61K047-00; C12N015-70; C07K017-00; A61K039-29;  
C12N015-09; C07K001-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 275 OF 367 USPATFULL on STN  
AN 2003:251033 USPATFULL  
TI Methods for identifying modulators of apoptosis  
IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES  
Guo, Bin, San Diego, CA, UNITED STATES  
PI US 2003175819 A1 20030918  
AI US 2002-306878 A1 20021127 (10)  
PRAI US 2001-334149P 20011128 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3438  
INCL INCLM: 435/007.200  
INCLS: 424/009.200  
NCL NCLM: 435/007.200  
NCLS: 424/009.200

ICM: G01N033-53

ICS: G01N033-567; G01N033-574; A61K049-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 276 OF 367 USPATFULL on STN  
AN 2003:250501 USPATFULL  
TI Innate immune system-directed vaccines  
IN Medzhitov, Ruslan M., Branford, CT, UNITED STATES  
Kopp, Elizabeth, Fairfield, CT, UNITED STATES  
PA Yale University, New Haven, CT (U.S. corporation)  
PI US 2003175287 A1 20030918  
AI US 2002-319854 A1 20021213 (10)  
RLI Continuation-in-part of Ser. No. US 2001-752832, filed on 3 Jan 2001,  
ABANDONED  
PRAI US 2001-340174P 20011214 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2991  
INCL INCLM: 424/185.100  
INCLS: 435/069.700; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 424/185.100  
NCLS: 435/069.700; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: A61K039-00  
ICS: C07H021-04; C12P021-04; C12N005-06; C07K014-47  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 277 OF 367 USPATFULL on STN  
AN 2003:244343 USPATFULL  
TI Alpha-fetoprotein peptides and uses thereof  
IN Andersen, Thomas T., Albany, NY, UNITED STATES  
Bennett, James A., Delmar, NY, UNITED STATES  
Jacobson, Herbert I., Albany, NY, UNITED STATES  
Mesfin, Fassil B., Albany, NY, UNITED STATES  
PI US 2003170752 A1 20030911  
AI US 2001-872623 A1 20010602 (9)  
PRAI US 2000-208614P 20000601 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1173  
INCL INCLM: 435/007.230  
INCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000  
NCL NCLM: 435/007.230  
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000  
IC [7]  
ICM: G01N033-574  
ICS: C07K007-08; C07K007-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 278 OF 367 USPATFULL on STN  
AN 2003:238482 USPATFULL  
TI Reverse-turn mimetics and methods relating thereto  
IN Urban, Jan, Kirkland, WA, UNITED STATES  
Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES  
Lee, Min S., Sammamish, WA, UNITED STATES  
PA Molecumetics, Ltd., Bellevue, WA (U.S. corporation)  
PI US 2003166640 A1 20030904  
AI US 2002-150481 A1 20020516 (10)  
PRAI US 2001-291663P 20010516 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1913  
INCL INCLM: 514/224.200  
INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;  
544/095.000; 544/014.000; 544/350.000; 544/345.000  
NCL NCLM: 514/224.200  
NCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;  
544/095.000; 544/014.000; 544/350.000; 544/345.000  
IC [7]  
ICM: G01N033-53  
ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 279 OF 367 USPATFULL on STN  
AN 2003:237328 USPATFULL

Protein S in relation to adult neural stem or progenitor cells

IN Bertilsson, Goran, Vasterhaninge, SWEDEN  
 Falk, Anna, Solna, SWEDEN  
 Frisen, Jonas, Stockholm, SWEDEN  
 Heidrich, Jessica, Arsta, SWEDEN  
 Hellstrom, Kristina, Sodertalje, SWEDEN  
 Kortesmaa, Jarkko, Stockholm, SWEDEN  
 Lindquist, Per, Bromma, SWEDEN  
 Lundh, Hanna, Solna, SWEDEN  
 McGuire, Jacqueline, Huddinge, SWEDEN  
 Mercer, Alex, Bromma, SWEDEN  
 Patrone, Cesare, Hagersten, SWEDEN  
 Ronnholm, Harriet, Trangsund, SWEDEN  
 Wikstrom, Lillian, Spanga, SWEDEN  
 Zachrisson, Olof, Spanga, SWEDEN

PI US 2003165485 A1 20030904  
 AI US 2002-291171 A1 20021108 (10)  
 PRAI US 2001-344725P 20011109 (60)  
 US 2002-393263P 20020702 (60)  
 US 2001-345064P 20011109 (60)  
 US 2002-394397P 20020708 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 3554  
 INCL INCLM: 424/094.600  
 INCLS: 424/146.100  
 NCL NCLM: 424/094.600  
 NCLS: 424/146.100  
 IC [7]  
 ICM: A61K038-46  
 ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 280 OF 367 USPATFULL on STN  
 AN 2003:225306 USPATFULL  
 TI Novel method for down-regulation of amyloid  
 IN Rasmussen, Peter Birk, Horsholm, DENMARK  
 Jensen, Martin Roland, Horsholm, DENMARK  
 Nielsen, Klaus Gregorius, Horsholm, DENMARK  
 Koefoed, Peter, Horsholm, DENMARK  
 Degan, Florence Dal, Horsholm, DENMARK

PI US 2003157117 A1 20030821  
 AI US 2002-223809 A1 20020820 (10)  
 PRAI DK 2001-1231 20010820  
 DK 2002-58 20020416  
 US 2001-337543P 20011022 (60)  
 US 2002-373027P 20020416 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 3681  
 INCL INCLM: 424/185.100  
 INCLS: 435/226.000  
 NCL NCLM: 424/185.100  
 NCLS: 435/226.000  
 IC [7]  
 ICM: A61K039-00  
 ICS: C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 281 OF 367 USPATFULL on STN  
 AN 2003:220227 USPATFULL  
 TI Activation and inhibition of the immune system  
 IN Foxwell, Brian, London, UNITED KINGDOM  
 Feldmann, Marc, London, UNITED KINGDOM

PI US 2003153518 A1 20030814  
 AI US 2003-168805 A1 20030131 (10)  
 WO 2000-GB4925 20001222  
 PRAI GB 1999-30616 19991224

DT Utility  
 FS APPLICATION  
 LN.CNT 2235  
 INCL INCLM: 514/044.000  
 INCLS: 424/185.100  
 NCL NCLM: 514/044.000  
 NCLS: 424/185.100

ICM: A61K048-00

ICS: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 282 OF 367 USPATFULL on STN  
AN 2003:200784 USPATFULL  
TI Immunogenic HBC chimera particles having enhanced stability  
IN Birkett, Ashley J., Escondido, CA, UNITED STATES  
PI US 2003138769 A1 20030724  
AI US 2001-930915 A1 20010815 (9)  
RLI Continuation-in-part of Ser. No. US 2000-226867, filed on 22 Aug 2000,  
PENDING Continuation-in-part of Ser. No. US 2000-225843, filed on 16 Aug  
2000, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 6993  
INCL INCLM: 435/005.000  
INCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100  
NCL NCLM: 435/005.000  
NCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100  
IC [7]  
ICM: C12Q001-70  
ICS: C12P021-02; C12N005-06; C07K014-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 283 OF 367 USPATFULL on STN  
AN 2003:166652 USPATFULL  
TI Treatments for neurotoxicity in alzheimer's disease  
IN Ingram, Vernon M., Cambridge, MA, UNITED STATES  
Blanchard, Barbara J., Cambridge, MA, UNITED STATES  
Stockwell, Brent R., Boston, MA, UNITED STATES  
PI US 2003114510 A1 20030619  
AI US 2002-51663 A1 20020118 (10)  
RLI Continuation-in-part of Ser. No. US 2000-706574, filed on 3 Nov 2000,  
PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 2115  
INCL INCLM: 514/417.000  
NCL NCLM: 514/417.000  
IC [7]  
ICM: A61K031-4035  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 284 OF 367 USPATFULL on STN  
AN 2003:165862 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2003113717 A1 20030619  
AI US 2001-893878 A1 20010629 (9)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED  
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED  
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15933  
INCL INCLM: 435/006.000  
INCLS: 435/007.200; 435/455.000; 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 435/007.200; 435/455.000; 435/091.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.



AN 2003:153484 USPATFULL  
TI Treatments for neurotoxicity in Alzheimer's disease  
IN Ingram, Vernon M., Cambridge, MA, UNITED STATES  
Blanchard, Barbara J., Cambridge, MA, UNITED STATES  
Stockwell, Brent R., Boston, MA, UNITED STATES  
PI US 2003105152 A1 20030605  
AI US 2002-143534 A1 20020510 (10)  
RLI Continuation-in-part of Ser. No. US 2002-51663, filed on 18 Jan 2002,  
PENDING Continuation-in-part of Ser. No. US 2000-706574, filed on 3 Nov  
2000, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 2249  
INCL INCLM: 514/417.000  
INCLS: 435/004.000  
NCL NCLM: 514/417.000  
NCLS: 435/004.000  
IC [7]  
ICM: A61K031-4035  
ICS: C12Q001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 286 OF 367 USPATFULL on STN  
AN 2003:146345 USPATFULL  
TI Metalloprotease-disintegrin ADAM23 (SVPH3-17)  
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES  
PA Immunex Corporation (U.S. corporation)  
PI US 2003100091 A1 20030529  
AI US 2002-202675 A1 20020723 (10)  
RLI Division of Ser. No. US 634252, PENDING Continuation of Ser. No. WO  
1999-US3016, filed on 11 Feb 1999, PENDING  
PRAI US 1998-74310P 19980211 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3070  
INCL INCLM: 435/196.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/196.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: C12N009-16  
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 287 OF 367 USPATFULL on STN  
AN 2003:146281 USPATFULL  
TI Methods and compositions using coiled binding partners  
IN Colyer, John, West Yorkshire, UNITED KINGDOM  
Lightowler, Joanne, York, UNITED KINGDOM  
PI US 2003100027 A1 20030529  
AI US 2000-491614 A1 20000126 (9)  
RLI Continuation-in-part of Ser. No. US 1999-259474, filed on 26 Feb 1999,  
ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 2588  
INCL INCLM: 435/007.400  
NCL NCLM: 435/007.400  
IC [7]  
ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 288 OF 367 USPATFULL on STN  
AN 2003:140906 USPATFULL  
TI Methods and compositions for the treatment of diseases associated with  
signal transduction aberrations  
IN Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES  
Ling, Song, Ann Arbor, MI, UNITED STATES  
PA The Regents Of The University Of Michigan (U.S. corporation)  
PI US 2003096748 A1 20030522  
AI US 2002-161959 A1 20020603 (10)  
PRAI US 2001-295691P 20010604 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2986

NCL INCL: 530/359.000  
NCLM: 514/012.000  
NCLS: 530/359.000  
IC [7]  
ICM: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 289 OF 367 USPATFULL on STN  
AN 2003:126727 USPATFULL  
TI Novel methods for down-regulation of amyloid  
IN Jensen, Martin Roland, Horsholm, DENMARK  
Birk, Peter, Horsholm, DENMARK  
Nielsen, Klaus Gregorius, Horsholm, DENMARK  
PI US 2003086938 A1 20030508  
AI US 2002-204362 A1 20020816 (10)  
WO 2001-DK113 20010219  
PRAI DK 2000-265 20000221  
DT Utility  
FS APPLICATION  
LN.CNT 3114  
INCL INCLM: 424/185.100  
NCL NCLM: 424/185.100  
IC [7]  
ICM: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 290 OF 367 USPATFULL on STN  
AN 2003:120290 USPATFULL  
TI Nucleic acids encoding human adamalysin SVPH1-8  
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES  
PA Immunex Corporation (U.S. corporation)  
PI US 2003082771 A1 20030501  
AI US 2002-265125 A1 20021003 (10)  
RLI Division of Ser. No. US 2000-617145, filed on 14 Jul 2000, GRANTED, Pat.  
No. US 6485956 Continuation of Ser. No. WO 1999-US603, filed on 12 Jan  
1999, PENDING  
PRAI US 1998-71505P 19980114 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2031  
INCL INCLM: 435/189.000  
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/189.000  
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-02; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 291 OF 367 USPATFULL on STN  
AN 2003:120026 USPATFULL  
TI Identification of modulatory molecules using inducible promoters  
IN Brown, Steven J., San Diego, CA, UNITED STATES  
Dunnington, Damien J., San Diego, CA, UNITED STATES  
Clark, Imran, San Diego, CA, UNITED STATES  
PI US 2003082511 A1 20030501  
AI US 2001-965201 A1 20010925 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 5526  
INCL INCLM: 435/004.000  
INCLS: 435/006.000  
NCL NCLM: 435/004.000  
NCLS: 435/006.000  
IC [7]  
ICM: C12Q001-00  
ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 292 OF 367 USPATFULL on STN  
AN 2003:113007 USPATFULL  
TI Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof  
IN Schubert, David R., La Jolla, CA, UNITED STATES  
Kashiwa, Atsushi, Yokohama, JAPAN  
Kimura, Hideo, Tokyo, JAPAN

AI US 2002-234961 A1 20020903 (10)  
 RLI Continuation of Ser. No. WO 2001-US7024, filed on 5 Mar 2001, PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4003  
 INCL INCLM: 435/069.100  
 INCLS: 435/320.100; 435/226.000; 435/325.000; 536/023.200  
 NCL NCLM: 435/069.100  
 NCLS: 435/320.100; 435/226.000; 435/325.000; 536/023.200  
 IC [7]  
 ICM: C12P021-02  
 ICS: C12N005-06; C07H021-04; C12N009-64  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 293 OF 367 USPATFULL on STN  
 AN 2003:112909 USPATFULL  
 TI Methods of suppressing microglial activation and systemic inflammatory responses  
 IN Laskowitz, Daniel T., Chapel Hill, NC, UNITED STATES  
 Matthew, William D., Durham, NC, UNITED STATES  
 McMillian, Michael, Rareton, NJ, UNITED STATES  
 PI US 2003077641 A1 20030424  
 AI US 2002-252120 A1 20020923 (10)  
 RLI Continuation-in-part of Ser. No. US 2001-957909, filed on 21 Sep 2001,  
 PENDING Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar  
 1999, ABANDONED  
 PRAI US 1998-77551P 19980311 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3107  
 INCL INCLM: 435/006.000  
 INCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100  
 NCL NCLM: 435/006.000  
 NCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100  
 IC [7]  
 ICM: A61K038-17  
 ICS: A61K038-10; C12Q001-68; A61K038-00; C12N007-00; C12N007-01;  
 C12N005-00; C12N005-02; A61K039-12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 294 OF 367 USPATFULL on STN  
 AN 2003:106698 USPATFULL  
 TI Yeast screens for treatment of human disease  
 IN Lindquist, Susan, Chestnut Hill, MA, UNITED STATES  
 Krobtsch, Sylvia, Berlin, GERMANY, FEDERAL REPUBLIC OF  
 Outeiro, Tiago Fleming, Cambridge, MA, UNITED STATES  
 PA The University of Chicago (U.S. corporation)  
 PI US 2003073610 A1 20030417  
 AI US 2002-77584 A1 20020215 (10)  
 PRAI US 2001-269157P 20010215 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3198  
 INCL INCLM: 514/001.000  
 INCLS: 435/007.310; 435/254.200; 435/483.000  
 NCL NCLM: 514/001.000  
 NCLS: 435/007.310; 435/254.200; 435/483.000  
 IC [7]  
 ICM: A61K031-00  
 ICS: G01N033-53; G01N033-569; C12N001-18; C12N015-74  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 295 OF 367 USPATFULL on STN  
 AN 2003:102440 USPATFULL  
 TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor  
 IN Zhang, Shuguang, Cambridge, MA, United States  
 Lockshin, Curtis, Lexington, MA, United States  
 Rich, Alexander, Cambridge, MA, United States  
 Holmes, Todd, Cambridge, MA, United States  
 PA Massachusetts Institute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI US 6548630 B1 20030415  
 AI US 1997-898300 19970722 (8)  
 RLI Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994, now

filed on 28 Dec 1992, now abandoned

DT Utility  
FS GRANTED  
LN.CNT 2187  
INCL INCLM: 530/300.000  
INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000;  
514/012.000; 514/013.000; 514/014.000  
NCL NCLM: 530/300.000  
NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000  
IC [7]  
ICM: C07K007-00  
ICS: C07K016-00; A61K038-00  
EXF 514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327;  
530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 296 OF 367 USPATFULL on STN  
AN 2003:99212 USPATFULL  
TI Anti-ADDL antibodies and uses thereof  
IN Klein, William L., Winnetka, IL, UNITED STATES  
Krafft, Grant A., Glenview, IL, UNITED STATES  
Lambert, Mary P., Glenview, IL, UNITED STATES  
Viola, Kirsten L., Chicago, IL, UNITED STATES  
Chromy, Brett A., Pleasanton, CA, UNITED STATES  
Gong, Yue Song, Evanston, IL, UNITED STATES  
Chang, Lei, Evanston, IL, UNITED STATES  
Morgan, Todd E., Los Angeles, CA, UNITED STATES  
Rozofsky, Irina, Pasadena, CA, UNITED STATES  
Finch, Caleb E., Altadena, CA, UNITED STATES  
PI US 2003068316 A1 20030410  
AI US 2002-166856 A1 20020611 (10)  
RLI Continuation-in-part of Ser. No. US 1999-369236, filed on 4 Aug 1999,  
PENDING Continuation-in-part of Ser. No. US 1997-796089, filed on 5 Feb  
1997, GRANTED, Pat. No. US 6218506  
PRAI US 1998-95264P 19980804 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2982  
INCL INCLM: 424/130.100  
NCL NCLM: 424/130.100  
IC [7]  
ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 297 OF 367 USPATFULL on STN  
AN 2003:37643 USPATFULL  
TI Methods of screening for agents that inhibit aggregation of polypeptides  
IN Housman, David E., Newton, MA, UNITED STATES  
Preisinger, Elizabeth A., Roslindale, MA, UNITED STATES  
Kazantsev, Aleksey G., Boston, MA, UNITED STATES  
PA Massachusetts Institute of Technology, a Massachusetts corporation (U.S.  
corporation)  
PI US 2003027288 A1 20030206  
AI US 2002-194584 A1 20020712 (10)  
RLI Division of Ser. No. US 1999-405048, filed on 27 Sep 1999, GRANTED, Pat.  
No. US 6420122  
DT Utility  
FS APPLICATION  
LN.CNT 1058  
INCL INCLM: 435/091.100  
INCLS: 435/091.330; 424/186.100; 424/208.100  
NCL NCLM: 435/091.100  
NCLS: 435/091.330; 424/186.100; 424/208.100  
IC [7]  
ICM: C12P019-34  
ICS: A61K039-12; A61K039-21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 298 OF 367 USPATFULL on STN  
AN 2003:30296 USPATFULL  
TI Protein aggregation assays and uses thereof  
IN Kondejewski, Les, St. Lazare, CANADA  
Chakrabartty, Avijit, Vaughan, CANADA  
Qi, Xiao-Fei, Toronto, CANADA  
Cashman, Neil, Toronto, CANADA

AI US 2002-176809 A1 20020620 (10)  
PRAI US 2001-299849P 20010620 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2602  
INCL INCLM: 435/007.100  
INCLS: 435/007.210  
NCL NCLM: 435/007.100  
NCLS: 435/007.210  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 299 OF 367 USPATFULL on STN  
AN 2003:4068 USPATFULL  
TI Method of preventing cell death using segments of neural thread proteins  
IN Averbach, Paul A., Beaconsfield, CANADA  
PI US 2003004107 A1 20030102  
AI US 2002-146130 A1 20020516 (10)  
PRAI US 2001-290971P 20010516 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1698  
INCL INCLM: 514/012.000  
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000  
NCL NCLM: 514/012.000  
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000  
IC [7]  
ICM: A61K038-17  
ICS: A61K038-10; A61K038-08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 300 OF 367 USPATFULL on STN  
AN 2003:4060 USPATFULL  
TI The use of copolymer 1 and related peptides and polypeptides and T cells  
treated therewith for neuroprotective therapy  
IN Eisenbach-schwartz, Michael, Rehovot, ISRAEL  
Cohen, Irun R., Rehovot, ISRAEL  
Sela, Michael, Rehovot, ISRAEL  
Yoles, Eti, Nahal Sorek, ISRAEL  
Kipnis, Jonathan, Modiin, ISRAEL  
PI US 2003004099 A1 20030102  
AI US 2001-765644 A1 20010122 (9)  
RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000,  
ABANDONED Continuation-in-part of Ser. No. US 2000-487793, filed on 20  
Jan 2000, ABANDONED  
PRAI US 2000-209799P 20000607 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2844  
INCL INCLM: 514/012.000  
INCLS: 424/093.700  
NCL NCLM: 514/012.000  
NCLS: 424/093.700  
IC [7]  
ICM: A61K045-00  
ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 301 OF 367 USPATFULL on STN  
AN 2003:3410 USPATFULL  
TI Method of preventing cell death using antibodies to neural thread  
proteins  
IN Averbach, Paul A., Quebec, CANADA  
PI US 2003003445 A1 20030102  
AI US 2002-138516 A1 20020506 (10)  
PRAI US 2001-288463P 20010504 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1705  
INCL INCLM: 435/005.000  
INCLS: 435/069.100; 435/345.000; 435/007.100  
NCL NCLM: 435/005.000  
NCLS: 435/069.100; 435/345.000; 435/007.100

ICM: C12Q001-70  
ICS: G01N033-53; C12P021-06; C12N005-06; C12N005-16  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 302 OF 367 USPATFULL on STN  
AN 2002:343880 USPATFULL  
TI Compositions and methods for monitoring the modification of modification  
dependent binding partner polypeptides  
IN Craig, Roger, Smallwood, UNITED KINGDOM  
PI US 2002197606 A1 20021226  
AI US 2001-770102 A1 20010125 (9)  
PRAI US 2000-179283P 20000131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3550  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]  
ICM: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 303 OF 367 USPATFULL on STN  
AN 2002:329478 USPATFULL  
TI Novel method for down-regulation of amyloid  
IN Jensen, Martin Roland, Holte, DENMARK  
Rasmussen, Peter Birk, Frederiksberg, DENMARK  
Nielsen, Klaus Gregorius, Soborg, DENMARK  
PI US 2002187157 A1 20021212  
AI US 2001-785215 A1 20010220 (9)  
PRAI PA 2000-200000265 20000221  
US 2000-186295P 20000301 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3272  
INCL INCLM: 424/185.100  
INCLS: 424/085.100; 424/085.200  
NCL NCLM: 424/185.100  
NCLS: 424/085.100; 424/085.200  
IC [7]  
ICM: A61K039-00  
ICS: A61K038-19; A61K038-20  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 304 OF 367 USPATFULL on STN  
AN 2002:310800 USPATFULL  
TI Testis-specific human SVPH1-8 proteinase  
IN Cerretti, Douglas P., Seattle, WA, United States  
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 6485956 B1 20021126  
AI US 2000-617145 20000714 (9)  
DT Utility  
FS GRANTED  
LN.CNT 2072  
INCL INCLM: 435/219.000  
INCLS: 435/069.100; 435/183.000; 435/218.000  
NCL NCLM: 435/219.000  
NCLS: 435/069.100; 435/183.000; 435/218.000  
IC [7]  
ICM: C12P021-06  
ICS: C12N009-00; C12N009-66; C12N009-50  
EXF 435/69.1; 435/183; 435/212; 435/219  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 305 OF 367 USPATFULL on STN  
AN 2002:308378 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting B-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES

Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002173504 A1 20021121  
AI US 2001-915519 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25650  
INCL INCLM: 514/212.040  
INCLS: 514/327.000; 514/424.000; 514/659.000  
NCL NCLM: 514/212.040  
NCLS: 514/327.000; 514/424.000; 514/659.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-4015; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 306 OF 367 USPATFULL on STN  
AN 2002:301123 USPATFULL  
TI Hybridization probe and target nucleic acid detecting kit, target  
nucleic acid detecting apparatus and target nucleic acid detecting  
method using the same  
IN Kinoshita, Takatoshi, Aichi, JAPAN  
Washizu, Shintaro, Shizuoka, JAPAN  
PA FUJI PHOTO FILM CO., LTD. (3)  
PI US 2002168666 A1 20021114  
AI US 2002-103830 A1 20020325 (10)  
PRAI JP 2001-86306 20010323  
DT Utility  
FS APPLICATION  
LN.CNT 1137  
INCL INCLM: 435/006.000  
INCLS: 536/024.300; 435/287.200  
NCL NCLM: 435/006.000  
NCLS: 536/024.300; 435/287.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12M001-34  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 307 OF 367 USPATFULL on STN  
AN 2002:295299 USPATFULL  
TI Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative  
disease  
IN Kirsch, Wolff M., Redlands, CA, UNITED STATES  
Lennart, Anto, Loma Linda, CA, UNITED STATES  
Kelln, Wayne J., Loma Linda, CA, UNITED STATES  
Kang, Dae-Kyung, Rockville, MD, UNITED STATES  
Levine, Rodney L., Rockville, MD, UNITED STATES  
Rouault, Tracey A., North Bethesda, MD, UNITED STATES  
PI US 2002165349 A1 20021107  
AI US 2001-924396 A1 20010806 (9)  
PRAI US 2000-222863P 20000804 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3514  
INCL INCLM: 530/350.000  
INCLS: 536/023.500; 435/006.000; 435/007.100  
NCL NCLM: 530/350.000  
NCLS: 536/023.500; 435/006.000; 435/007.100  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; C07H021-04; C07K014-705

L5 ANSWER 308 OF 367 USPATFULL on STN  
 AN 2002:294746 USPATFULL  
 TI Methods of suppressing microglial activation  
 IN Laskowitz, Daniel T., Chapel Hill, NC, UNITED STATES  
 Matthew, William D., Durham, NC, UNITED STATES  
 McMillian, Michael, Rareton, NJ, UNITED STATES  
 PI US 2002164789 A1 20021107  
 AI US 2001-957909 A1 20010921 (9)  
 RLI Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar 1999,  
 PENDING  
 PRAI US 1998-77551P 19980311 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1534  
 INCL INCLM: 435/343.000  
 INCLS: 514/012.000; 514/044.000; 435/005.000  
 NCL NCLM: 435/343.000  
 NCLS: 514/012.000; 514/044.000; 435/005.000  
 IC [7]  
 ICM: A61K038-17  
 ICS: C12Q001-70; A61K038-00; A61K031-70; A01N043-04; C12N005-06;  
 C12N005-16  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 309 OF 367 USPATFULL on STN  
 AN 2002:290938 USPATFULL  
 TI N-hydroxy 4-sulfonyl butanamide compounds  
 IN Villamil, Clara I., Glenview, IL, United States  
 Freskos, John N., Clayton, MO, United States  
 Mischke, Brent V., Defiance, MO, United States  
 Mullins, Patrick B., St. Louis, MO, United States  
 Heintz, Robert M., Ballwin, MO, United States  
 Getman, Daniel P., Chesterfield, MO, United States  
 McDonald, Joseph J., Ballwin, MO, United States  
 DeCrescenzo, Gary A., St. Charles, MO, United States  
 Barta, Thomas E., Evanston, IL, United States  
 Becker, Daniel P., Glenview, IL, United States  
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
 PI US 6476027 B1 20021105  
 WO 9839316 19980911  
 AI US 1999-254531 19991206 (9)  
 WO 1998-US4297 19980304  
 19991206 PCT 371 date  
 PRAI US 1997-35182P 19970304 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3634  
 INCL INCLM: 514/237.800  
 INCLS: 514/330.000; 514/331.000; 514/357.000; 514/428.000; 514/486.000;  
 514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000;  
 546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000  
 NCL NCLM: 514/237.800  
 NCLS: 514/330.000; 514/331.000; 514/357.000; 514/428.000; 514/486.000;  
 514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000;  
 546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000  
 IC [7]  
 ICM: A61K031-16  
 ICS: A61K031-4406; C07C323-32; C07D211-90  
 EXF 562/621; 562/623; 546/225; 546/226; 546/233; 546/340; 544/159; 548/568;  
 560/13; 514/237.8; 514/330; 514/331; 514/357; 514/428; 514/456; 514/575  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 310 OF 367 USPATFULL on STN  
 AN 2002:273410 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
 compositions comprising same, and methods for inhibiting beta-amyloid  
 peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES



Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James A., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002151538 A1 20021017  
US 6579867 B2 20030617  
AI US 2001-915379 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 26543  
INCL INCLM: 514/212.040  
INCLS: 514/327.000; 514/424.000; 514/659.000  
NCL NCLM: 514/211.060  
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-4015; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 311 OF 367 USPATFULL on STN  
AN 2002:273336 USPATFULL  
TI Methods for preventing neural tissue damage and for the treatment of  
alpha-synuclein diseases  
IN Wolozin, Benjamin, Hinsdale, IL, UNITED STATES  
Ostretova-Golts, Natalie, Forrest Park, IL, UNITED STATES  
Lebowitz, Michael S., Baltimore, MD, UNITED STATES  
PI US 2002151464 A1 20021017  
US 6780971 B2 20040824  
AI US 2001-901187 A1 20010709 (9)  
PRAI US 2000-217319P 20000707 (60)  
US 2001-279199P 20010328 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1374  
INCL INCLM: 514/002.000  
INCLS: 435/007.200; 435/025.000  
NCL NCLM: 530/329.000  
NCLS: 514/002.000; 514/016.000  
IC [7]  
ICM: A61K038-16  
ICS: G01N033-53; G01N033-567; C12Q001-26  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 312 OF 367 USPATFULL on STN  
AN 2002:272761 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2002150881 A1 20021017  
AI US 2001-781988 A1 20010214 (9)  
RLI Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED  
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED  
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15696  
INCL INCLM: 435/005.000

NCL NCLM: 435/005.000  
NCLS: 435/006.000; 435/007.100; 435/235.100

IC [7]  
ICM: C12Q001-70  
ICS: C12Q001-68; G01N033-53; C12N007-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 313 OF 367 USPATFULL on STN  
AN 2002:259378 USPATFULL  
TI Methods for enhancing the bioavailability of a drug  
IN Hayward, Neil J., North Grafton, MA, UNITED STATES  
Gefter, Malcolm L., Lincoln, MA, UNITED STATES  
PI US 2002142950 A1 20021003  
AI US 2001-781133 A1 20010209 (9)  
PRAI US 2000-181833P 20000211 (60)  
US 2000-181943P 20000211 (60)

DT Utility  
FS APPLICATION

LN.CNT 2566

INCL INCLM: 514/012.000  
INCLS: 514/224.800

NCL NCLM: 514/012.000  
NCLS: 514/224.800

IC [7]  
ICM: A61K038-17  
ICS: A61K031-5415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 314 OF 367 USPATFULL on STN  
AN 2002:251785 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting beta-amyloid  
peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002137738 A1 20020926  
US 6559141 B2 20030506  
AI US 2001-915564 A1 20010727 (9)

RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING

PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS APPLICATION

LN.CNT 26049

INCL INCLM: 514/212.030  
INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/211.060  
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
540/527.000

IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 315 OF 367 USPATFULL on STN  
AN 2002:243567 USPATFULL

with molecular crystallization  
IN Shell, John W., Hillsborough, CA, UNITED STATES  
PI US 2002132758 A1 20020919  
AI US 2002-52712 A1 20020117 (10)  
PRAI US 2001-262987P 20010118 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1620  
INCL INCLM: 514/002.000  
INCLS: 435/007.100  
NCL NCLM: 514/002.000  
NCLS: 435/007.100  
IC [7]  
ICM: G01N033-53  
ICS: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 316 OF 367 USPATFULL on STN  
AN 2002:228326 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002123486 A1 20020905  
US 6632811 B2 20031014  
AI US 2001-915342 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 26177  
INCL INCLM: 514/212.020  
INCLS: 514/659.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 317 OF 367 USPATFULL on STN  
AN 2002:227618 USPATFULL  
TI Ascorbic acid analogs for metalloradiopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2002122769 A1 20020905  
US 6713042 B2 20040330  
AI US 2002-81258 A1 20020222 (10)  
PRAI US 2001-271389P 20010226 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1882  
INCL INCLM: 424/001.110  
INCLS: 514/424.000; 514/474.000; 514/690.000  
NCL NCLM: 424/001.650  
NCLS: 424/001.110; 424/009.100; 548/400.000; 548/401.000; 549/200.000;

IC [7]  
ICM: A61K051-00  
ICS: A61K031-4015; A61K031-375  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 318 OF 367 USPATFULL on STN  
AN 2002:227617 USPATFULL  
TI Stable radiopharmaceutical compositions and methods for preparation thereof  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
Barrett, John A., Groton, MA, UNITED STATES  
Carpenter, Alan P., JR., Carlisle, MA, UNITED STATES  
PI US 2002122768 A1 20020905  
AI US 2001-899629 A1 20010705 (9)  
PRAI US 2000-216396P 20000706 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4115  
INCL INCLM: 424/001.110  
NCL NCLM: 424/001.110  
IC [7]

ICM: A61K051-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 319 OF 367 USPATFULL on STN  
AN 2002:224705 USPATFULL  
TI Hydrophobically-modified hedgehog protein compositions and methods  
IN Pepinsky, R. Blake, Arlington, MA, United States  
Baker, Darren P., Hingham, MA, United States  
Wen, Dingyi, Waltham, MA, United States  
Williams, Kevin P., Natick, MA, United States  
Garber, Ellen A., Cambridge, MA, United States  
Taylor, Frederick R., Milton, MA, United States  
Galdes, Alphonse, Lexington, MA, United States  
Porter, Jeffrey, Cambridge, MA, United States  
PA Curis, Inc., Cambridge, MA, United States (U.S. corporation)  
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6444793 B1 20020903  
AI US 1999-325256 19990603 (9)  
RLI Continuation of Ser. No. WO 1998-US25676, filed on 3 Dec 1998  
PRAI US 1998-99800P 19980910 (60)  
US 1998-89685P 19980617 (60)  
US 1998-78935P 19980320 (60)  
US 1997-67423P 19971203 (60)  
DT Utility  
FS GRANTED  
LN.CNT 5426  
INCL INCLM: 530/402.000  
INCLS: 530/350.000; 530/399.000; 530/359.000; 436/071.000; 514/012.000;  
514/506.000; 514/762.000  
NCL NCLM: 530/402.000  
NCLS: 436/071.000; 530/350.000; 530/359.000; 530/399.000  
IC [7]

ICM: C07K014-435  
ICS: C07K001-107  
EXF 436/71; 530/350; 530/399; 530/402; 530/359; 514/12; 514/506; 514/762  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 320 OF 367 USPATFULL on STN  
AN 2002:221784 USPATFULL  
TI Inhibitors of IAPP fibril formation and uses thereof  
IN Fraser, Paul, Toronto, CANADA  
PI US 2002119926 A1 20020829  
AI US 2001-956625 A1 20010919 (9)  
PRAI US 2000-233482P 20000919 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1753  
INCL INCLM: 514/012.000  
INCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000  
NCL NCLM: 514/012.000  
NCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000  
IC [7]  
ICM: A61K038-17  
ICS: A61K038-10; A61K038-08; C12N009-99

L5 ANSWER 321 OF 367 USPATFULL on STN  
AN 2002:216831 USPATFULL  
TI Epithelial cell targeting agent  
IN Hein, Mich B., Fallbrook, CA, United States  
Hiatt, Andrew C., San Diego, CA, United States  
Fitchen, John H., La Jolla, CA, United States  
PA Epicyte Pharmaceutical, Inc., San Diego, CA, United States (U.S.  
corporation)  
PI US 6440419 B1 20020827  
AI US 1998-176741 19981020 (9)  
RLI Continuation-in-part of Ser. No. US 1997-954211, filed on 20 Oct 1997,  
now patented, Pat. No. US 6251392  
DT Utility  
FS GRANTED  
LN.CNT 3177  
INCL INCLM: 424/178.100  
INCLS: 424/134.100; 424/143.100; 424/172.100; 514/002.000  
NCL NCLM: 424/178.100  
NCLS: 424/134.100; 424/143.100; 424/172.100; 514/002.000  
IC [7]  
ICM: A61K039-395  
EXF 435/320.1; 435/455; 536/23.1; 536/24.5; 514/44; 514/2; 512/2; 424/134.1;  
424/143.1; 424/172.1; 424/178.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 322 OF 367 USPATFULL on STN  
AN 2002:214328 USPATFULL  
TI Amyloid targeting imaging agents and uses thereof  
IN Gervais, Francine, Ile Bizard, CANADA  
Kong, Xianqi, Dollard-des-Ormeaux, CANADA  
Chalifour, Robert, Ile Bizard, CANADA  
Migneault, David, Laval, CANADA  
PI US 2002115717 A1 20020822  
AI US 2001-915092 A1 20010724 (9)  
PRAI US 2000-220808P 20000725 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2210  
INCL INCLM: 514/553.000  
INCLS: 424/001.110  
NCL NCLM: 514/553.000  
NCLS: 424/001.110  
IC [7]  
ICM: A61K031-185  
ICS: A61K051-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 323 OF 367 USPATFULL on STN  
AN 2002:214264 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting beta-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002115652 A1 20020822

AI US 2001-915362 A1 20010727 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 25618  
 INCL INCLM: 514/212.010  
 INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000  
 NCL NCLM: 514/211.060  
 NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
 540/527.000  
 IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 324 OF 367 USPATFULL on STN  
 AN 2002:206646 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
 compositions comprising same, and methods for inhibiting beta-Amyloid  
 peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 Varghese, John, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James E., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2002111343 A1 20020815  
 AI US 2001-915547 A1 20010727 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 25803  
 INCL INCLM: 514/212.030  
 INCLS: 514/327.000; 514/424.000; 514/659.000  
 NCL NCLM: 514/212.030  
 NCLS: 514/327.000; 514/424.000; 514/659.000  
 IC [7]  
 ICM: A61K031-55  
 ICS: A61K031-445; A61K031-4015; A61K031-13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 325 OF 367 USPATFULL on STN  
 AN 2002:192279 USPATFULL  
 TI Sequences characteristic of hypoxia-regulated gene transcription  
 IN Einat, Paz, Nes-Ziona, ISRAEL  
 Skaliter, Rami, Nes-Zional, ISRAEL  
 Feinstein, Elena, Rehovot, ISRAEL  
 PI US 2002103353 A1 20020801  
 AI US 2001-802472 A1 20010309 (9)  
 RLI Continuation-in-part of Ser. No. US 1999-384096, filed on 27 Aug 1999,  
 ABANDONED Continuation-in-part of Ser. No. US 1998-138109, filed on 21  
 Aug 1998, ABANDONED  
 PRAI US 1998-98158P 19980827 (60)  
 US 2001-132684P 20010905 (60)  
 US 1997-56453P 19970821 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 536/023.200  
INCLS: 435/320.100; 435/325.000; 435/069.100  
NCL NCLM: 536/023.200  
NCLS: 435/320.100; 435/325.000; 435/069.100  
IC [7]  
ICM: C07H021-04  
ICS: C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 326 OF 367 USPATFULL on STN  
AN 2002:185265 USPATFULL  
TI Modulators of amyloid aggregation  
IN Findeis, Mark A., Cambridge, MA, UNITED STATES  
Benjamin, Howard, Lexington, MA, UNITED STATES  
Garnick, Marc B., Brookline, MA, UNITED STATES  
Geffer, Malcolm L., Lincoln, MA, UNITED STATES  
Hundal, Arvind, Brighton, MA, UNITED STATES  
Kasman, Laura, Athens, GA, UNITED STATES  
Musso, Gary, Hopkinton, MA, UNITED STATES  
Signer, Ethan R., Cambridge, MA, UNITED STATES  
Wakefield, James, Brookline, MA, UNITED STATES  
Reed, Michael J., Marietta, GA, UNITED STATES  
PA Praecis Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2002098173 A1 20020725  
AI US 2001-972475 A1 20011004 (9)  
RLI Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, PATENTED  
Continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995,  
PATENTED Continuation-in-part of Ser. No. US 1995-404831, filed on 14  
Mar 1995, PATENTED Continuation-in-part of Ser. No. US 1995-548998,  
filed on 27 Oct 1995, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4009  
INCL INCLM: 424/094.300  
INCLS: 435/226.000  
NCL NCLM: 424/094.300  
NCLS: 435/226.000  
IC [7]  
ICM: A61K038-54  
ICS: C12N009-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 327 OF 367 USPATFULL on STN  
AN 2002:185242 USPATFULL  
TI New macrocyclic chelants useful for metallopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2002098149 A1 20020725  
US 6517814 B2 20030211  
AI US 2001-33765 A1 20011227 (10)  
PRAI US 2001-260500P 20010109 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1855  
INCL INCLM: 424/001.650  
NCL NCLM: 424/009.360  
NCLS: 424/001.110; 424/001.650; 424/009.100; 424/009.300; 424/009.361;  
424/009.362; 424/009.400; 534/010.000; 534/014.000  
IC [7]  
ICM: A61K051-00  
ICS: A61M036-14  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 328 OF 367 USPATFULL on STN  
AN 2002:179167 USPATFULL  
TI Peptide binding the KLVFF-sequence of \*\*\*amyloid\*\*\* - \*\*\*beta\*\*\*  
IN Nordstedt, Christer, Mulhouse, FRANCE  
Naslund, Jan, Stockholm, SWEDEN  
Thyberg, Johan, Stockholm, SWEDEN  
Tjernberg, Lars O., Spanga, SWEDEN  
Terenius, Lars, Uppsala, SWEDEN  
PI US 2002094957 A1 20020718  
AI US 2001-850061 A1 20010508 (9)  
RLI Division of Ser. No. US 1998-95106, filed on 10 Jun 1998, PENDING  
Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec 1996, UNKNOWN  
PRAI SE 1995-4467 19951212

DT Utility  
FS APPLICATION  
LN.CNT 727  
INCL INCLM: 514/015.000  
INCLS: 514/016.000; 530/328.000; 530/329.000  
NCL NCLM: 514/015.000  
NCLS: 514/016.000; 530/328.000; 530/329.000  
IC [7]  
ICM: A61K038-10  
ICS: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 329 OF 367 USPATFULL on STN  
AN 2002:178530 USPATFULL  
TI Polypodal chelants for metallopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2002094316 A1 20020718  
AI US 2001-33769 A1 20011227 (10)  
PRAI US 2001-260618P 20010109 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2716  
INCL INCLM: 424/001.110  
NCL NCLM: 424/001.110  
IC [7]  
ICM: A61K051-00  
ICS: A61M036-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 330 OF 367 USPATFULL on STN  
AN 2002:174955 USPATFULL  
TI Methods of screening for agents that inhibit aggregation of polypeptides  
IN Housman, David E., Newton, MA, United States  
Preisinger, Elizabeth A., Roslindale, MA, United States  
Kazantsev, Aleksey G., Boston, MA, United States  
PA Massachusetts Institute of Technology, Boston, MA, United States (U.S. corporation)  
PI US 6420122 B1 20020716  
AI US 1999-405048 19990927 (9)  
DT Utility  
FS GRANTED  
LN.CNT 1135  
INCL INCLM: 435/007.100  
INCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000  
NCL NCLM: 435/007.100  
NCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000  
IC [7]  
ICM: G01N033-53  
EXF 436/86; 436/501; 536/23.4; 530/300; 530/350; 435/7.1; 435/4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 331 OF 367 USPATFULL on STN  
AN 2002:148656 USPATFULL  
TI Compositions and methods for modulating TGF-beta signaling  
IN Wang, Tongwen, Seattle, WA, UNITED STATES  
PI US 2002076799 A1 20020620  
AI US 2001-927738 A1 20010810 (9)  
RLI Continuation-in-part of Ser. No. WO 2000-US3561, filed on 11 Feb 2000, UNKNOWN  
PRAI US 1999-119786P 19990211 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5961  
INCL INCLM: 435/226.000  
INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260; 536/023.200  
NCL NCLM: 435/226.000  
NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260; 536/023.200  
IC [7]  
ICM: C12N009-64  
ICS: C12N009-00; C07H021-04; C12P021-02; C12N005-06; C07K016-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 332 OF 367 USPATFULL on STN



TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002068741 A1 20020606  
AI US 2001-915263 A1 20010726 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25726  
INCL INCLM: 514/248.000  
INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;  
514/410.000; 514/411.000  
NCL NCLM: 514/248.000  
NCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;  
514/410.000; 514/411.000  
IC [7]  
ICM: A61K031-517  
ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 333 OF 367 USPATFULL on STN  
AN 2002:119332 USPATFULL  
TI Innate immune system-directed vaccines  
IN Medzhitov, Ruslan, New Haven, CT, UNITED STATES  
PI US 2002061312 A1 20020523  
AI US 2001-752832 A1 20010103 (9)  
PRAI US 2000-222042P 20000731 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2414  
INCL INCLM: 424/192.100  
INCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400  
NCL NCLM: 424/192.100  
NCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400  
IC [7]  
ICM: A61K039-35  
ICS: C12N005-10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 334 OF 367 USPATFULL on STN  
AN 2002:106291 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES

Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002055500 A1 20020509  
AI US 2001-916440 A1 20010730 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS APPLICATION

LN.CNT 25439

INCL INCLM: 514/212.030  
INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/212.030  
NCLS: 514/327.000; 514/424.000; 514/659.000

IC [7]  
ICM: A61K031-55  
ICS: A61K031-45; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 335 OF 367 USPATFULL on STN

AN 2002:99458 USPATFULL

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002052359 A1 20020502  
US 6544978 B2 20030408  
AI US 2001-915480 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS APPLICATION

LN.CNT 25908

INCL INCLM: 514/212.010  
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000;  
514/676.000

NCL NCLM: 514/211.060  
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
540/527.000

IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 336 OF 367 USPATFULL on STN

AN 2002:85701 USPATFULL

compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James A., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Indianapolis, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002045747 A1 20020418  
AI US 2001-916282 A1 20010730 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS APPLICATION

LN.CNT 26053

INCL INCLM: 540/450.000  
INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000

NCL NCLM: 540/450.000  
NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000

IC [7]  
ICM: A61K031-551  
ICS: C07D243-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 337 OF 367 USPATFULL on STN

AN 2002:67195 USPATFULL

TI Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

IN Eisenbach-Schwartz, Michal, Rehovot, ISRAEL  
Yoles, Eti, Rehovot, ISRAEL

Kipnis, Jonathan, Modiin, ISRAEL

PI US 2002037848 A1 20020328

AI US 2001-765301 A1 20010122 (9)

RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000, PENDING

PRAI US 2000-209799P 20000607 (60)

DT Utility

FS APPLICATION

LN.CNT 2839

INCL INCLM: 514/012.000

NCL NCLM: 514/012.000

IC [7]

ICM: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 338 OF 367 USPATFULL on STN

AN 2002:37903 USPATFULL

TI Compounds to treat alzheimer's disease

IN Hom, Roy, San Francisco, CA, UNITED STATES

Mamo, Shumeye, Oakland, CA, UNITED STATES

Tung, Jay, Belmont, CA, UNITED STATES

Gailunas, Andrea, San Francisco, CA, UNITED STATES

John, Varghese, San Francisco, CA, UNITED STATES

Fang, Lawrence Y., Foster City, CA, UNITED STATES

PI US 2002022623 A1 20020221

US 6737420 B2 20040518

AI US 2001-815960 A1 20010323 (9)

PRAI US 2000-191528P 20000323 (60)

DT Utility

FS APPLICATION

INCL INCLM: 514/227.800  
INCLS: 544/060.000; 514/233.500; 514/417.000; 514/534.000; 544/144.000;  
560/041.000; 548/473.000  
NCL NCLM: 514/218.000  
NCLS: 514/227.500; 514/231.200; 514/315.000; 514/317.000; 514/330.000;  
514/331.000; 514/451.000; 514/461.000; 514/471.000; 514/618.000;  
514/619.000; 540/492.000; 544/058.200; 544/059.000; 544/106.000;  
544/358.000; 544/359.000; 546/192.000; 548/400.000; 548/561.000;  
549/074.000; 549/426.000; 549/491.000; 549/497.000; 564/153.000;  
564/156.000; 564/167.000

IC [7]  
ICM: A61K031-541  
ICS: A61K031-5377; A61K031-4035; A61K031-24; C07D417-02; C07D413-02;  
C07D209-48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 339 OF 367 USPATFULL on STN  
AN 2002:32581 USPATFULL  
TI Methods to treat alzheimer's disease  
IN Hom, Roy, San Francisco, CA, UNITED STATES  
Mamo, Shumeye S., Oakland, CA, UNITED STATES  
Tung, Jay, Belmont, CA, UNITED STATES  
Gailunas, Andrea, San Francisco, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Fang, Lawrence Y., Foster City, CA, UNITED STATES  
PI US 2002019403 A1 20020214  
AI US 2001-816876 A1 20010323 (9)  
PRAI US 2000-191528P 20000323 (60)

DT Utility  
FS APPLICATION

LN.CNT 8655

INCL INCLM: 514/256.000  
INCLS: 514/519.000; 514/520.000; 514/534.000  
NCL NCLM: 514/256.000  
NCLS: 514/519.000; 514/520.000; 514/534.000

IC [7]  
ICM: A61K031-505  
ICS: A61K031-275; A61K031-277; A61K031-24  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 340 OF 367 USPATFULL on STN  
AN 2002:21796 USPATFULL  
TI Ternary ligand complexes useful as radiopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2002012631 A1 20020131  
US 6534038 B2 20030318  
AI US 2001-826449 A1 20010405 (9)  
PRAI US 2000-195235P 20000407 (60)

DT Utility  
FS APPLICATION

LN.CNT 2595

INCL INCLM: 424/009.360  
INCLS: 546/022.000; 562/007.000; 562/406.000; 564/015.000; 562/008.000;  
568/013.000  
NCL NCLM: 424/009.100  
NCLS: 424/001.110; 424/001.650; 424/001.730; 534/014.000; 568/017.000

IC [7]  
ICM: C07F009-58  
ICS: C07F009-28  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 341 OF 367 USPATFULL on STN  
AN 2002:8035 USPATFULL  
TI Macrocyclic chelants for metallopharmaceuticals  
IN Liu, Shuang, Chelmsford, MA, UNITED STATES  
PI US 2002004032 A1 20020110  
US 6565828 B2 20030520  
AI US 2001-826549 A1 20010405 (9)  
PRAI US 2000-195234P 20000407 (60)

DT Utility  
FS APPLICATION

LN.CNT 2981

INCL INCLM: 424/009.363  
INCLS: 540/474.000  
NCL NCLM: 424/001.530

IC [7]  
ICM: A61K049-12  
ICS: C07D257-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 342 OF 367 USPATFULL on STN  
AN 2001:235319 USPATFULL  
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof  
IN Markland, William, Milford, MA, United States  
Ladner, Robert Charles, Ijamsville, MD, United States  
PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)  
PI US 6333402 B1 20011225  
AI US 1999-421097 19991019 (9)  
RLI Division of Ser. No. US 1994-208264, filed on 10 Mar 1994, now patented,  
Pat. No. US 6057287 Continuation-in-part of Ser. No. US 1994-179964,  
filed on 11 Jan 1994, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 3154  
INCL INCLM: 536/023.500  
INCLS: 536/023.200; 435/007.000; 435/252.300; 435/320.100; 530/317.000  
NCL NCLM: 536/023.500  
NCLS: 435/007.100; 435/252.300; 435/254.230; 435/320.100; 435/325.000;  
530/317.000; 536/023.200

IC [7]  
ICM: C07H021-04  
ICS: A61K038-12; C12N001-20; C12N015-00; G01N033-53  
EXF 435/7; 435/252.3; 435/320.1; 514/2; 530/317; 536/23.1; 536/23.2;  
536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 343 OF 367 USPATFULL on STN  
AN 2001:233130 USPATFULL  
TI LIGAND BINDING SITE OF RAGE AND USES THEREOF  
IN STERN, DAVID, GREAT NECK, NY, United States  
YAN, SHI DU, NEW YORK, NY, United States  
SCHMIDT, ANN MARIE, FRANKLIN LAKE, NJ, United States  
LAMSTER, IRA, WYCKOFF, NJ, United States  
PI US 2001053357 A1 20011220  
US 6555651 B2 20030429  
AI US 1997-948131 A1 19971009 (8)  
DT Utility  
FS APPLICATION  
LN.CNT 2374  
INCL INCLM: 424/130.100  
INCLS: 530/350.000; 514/002.000; 514/012.000  
NCL NCLM: 530/324.000  
NCLS: 530/300.000

IC [7]  
ICM: A61K038-04  
ICS: A61K039-395; C07K014-705; C07K014-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 344 OF 367 USPATFULL on STN  
AN 2001:231187 USPATFULL  
TI Peptide binding the KLVFF-sequence of \*\*\*amyloid\*\*\* -. \*\*\*beta\*\*\*  
IN Nordstedt, Christer, Mulhouse, France  
Naslund, Jan, New York, NY, United States  
Thyberg, Johan, Stockholm, Sweden  
Tjernberg, Lars O., Spanga, Sweden  
Terenius, Lars, Uppsala, Sweden  
PA Karolinska Innovations AB, Stockholm, Sweden (non-U.S. corporation)  
PI US 6331440 B1 20011218  
AI US 1998-95106 19980610 (9)  
RLI Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec 1996  
PRAI SE 1995-4467 19951212  
US 1995-9386P 19951229 (60)  
DT Utility  
FS GRANTED  
LN.CNT 541  
INCL INCLM: 436/501.000  
INCLS: 435/007.100; 514/002.000; 514/017.000; 514/018.000  
NCL NCLM: 436/501.000  
NCLS: 435/007.100; 514/002.000; 514/017.000; 514/018.000

ICM: G01N033-566  
ICS: G01N033-53; A61K038-08  
EXF 435/7.1; 435/7.2; 436/501; 514/17; 514/18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 345 OF 367 USPATFULL on STN  
AN 2001:121586 USPATFULL  
TI Intracellular \*\*\*amyloid\*\*\* - \*\*\*beta\*\*\* peptide binding (ERAB)  
polypeptide  
IN Stern, David M., Great Neck, NY, United States  
Yan, Shi Du, New York, NY, United States  
PA The Trustees of Columbia University in the City of New York, New York,  
NY, United States (U.S. corporation)  
PI US 6268479 B1 20010731  
AI US 1997-815225 19970312 (8)  
DT Utility  
FS GRANTED  
LN.CNT 1529  
INCL INCLM: 530/350.000  
INCLS: 930/010.000  
NCL NCLM: 530/350.000  
NCLS: 930/010.000  
IC [7]  
ICM: C07K014-435  
EXF 530/350; 930/10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 346 OF 367 USPATFULL on STN  
AN 2001:97417 USPATFULL  
TI Epithelial cell targeting agent  
IN Hein, Mich B., Fallbrook, CA, United States  
Hiatt, Andrew C., San Diego, CA, United States  
Fitchen, John H., La Jolla, CA, United States  
PA Epicyte Pharmaceuticals, Inc., San Diego, CA, United States (U.S.  
corporation)  
PI US 6251392 B1 20010626  
AI US 1997-954211 19971020 (8)  
DT Utility  
FS GRANTED  
LN.CNT 2520  
INCL INCLM: 424/134.100  
INCLS: 435/188.000; 424/143.100; 424/172.100; 424/174.100; 424/182.100;  
424/183.100; 530/861.000; 530/863.000; 530/387.100  
NCL NCLM: 424/134.100  
NCLS: 424/143.100; 424/172.100; 424/174.100; 424/182.100; 424/183.100;  
435/188.000; 530/387.100; 530/861.000; 530/863.000  
IC [7]  
ICM: A61K039-395  
ICS: C12N009-96; C07K016-00  
EXF 530/861; 530/863; 530/864; 530/865; 530/866; 530/391.5; 530/391.7;  
530/391.9; 530/387.1; 435/188; 435/188.5; 435/195; 435/219; 424/179.1;  
424/180.1; 424/181.1; 424/183.1; 424/134.1; 424/138.1; 424/143.1;  
424/182.1; 424/172.1; 424/174.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 347 OF 367 USPATFULL on STN  
AN 2001:71330 USPATFULL  
TI Recombinant helix modification recognition proteins and uses thereof  
IN Kmiec, Eric B., Malvern, PA, United States  
Holloman, William K., Yorktown Heights, NY, United States  
Gerhold, David, Lansdale, PA, United States  
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 6232095 B1 20010515  
AI US 1995-563524 19951128 (8)  
DT Utility  
FS Granted  
LN.CNT 1621  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 435/069.700; 435/252.300; 536/023.400;  
536/023.740; 530/350.000; 530/371.000  
NCL NCLM: 435/069.100  
NCLS: 435/069.700; 435/252.300; 435/320.100; 435/325.000; 530/350.000;  
530/371.000; 536/023.400; 536/023.740  
IC [7]

ICS: C12N015-63; C12N001-20; C12N015-85; C07H021-04; C07K014-00  
EXF 435/6; 435/252.3; 435/69.1; 435/69.7; 435/325; 435/320.1; 530/350;  
530/371; 530/387.1; 536/23.1; 536/23.4; 536/23.74; 424/130.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 348 OF 367 USPATFULL on STN  
AN 2001:14622 USPATFULL  
TI Peptide nucleic acid conjugates  
IN Wickstrom, Eric, Philadelphia, PA, United States  
Basu, Soumitra, New Haven, CT, United States  
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 6180767 B1 20010130  
AI US 1997-779072 19970107 (8)  
PRAI US 1996-9747P 19960111 (60)  
DT Utility  
FS Granted  
LN.CNT 1510  
INCL INCLM: 536/022.100  
INCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;  
536/025.330; 536/025.340  
NCL NCLM: 536/022.100  
NCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;  
536/025.330; 536/025.340

IC [7]  
ICM: C07H019-00  
ICS: C07H021-02; C07H021-00; C07H021-04  
EXF 536/22.1; 536/23.1; 536/25.3; 536/25.31; 536/25.32; 536/25.33;  
536/25.34; 435/6  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 349 OF 367 USPATFULL on STN  
AN 2001:4934 USPATFULL  
TI Polyamine analogues as therapeutic and diagnostic agents  
IN Vermeulin, Nicolaas M. J., Woodinville, WA, United States  
O'Day, Christine L., Mountlake Terrace, WA, United States  
Webb, Heather K., Seattle, WA, United States  
Burns, Mark R., Shoreline, WA, United States  
Bergstrom, Donald E., West Lafayette, IN, United States  
PA Oridigm Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 6172261 B1 20010109  
WO 9903823 19990128  
AI US 1999-341400 19990903 (9)  
WO 1998-US14896 19980715  
19990903 PCT 371 date  
19990903 PCT 102(e) date  
PRAI US 1997-52586P 19970715 (60)  
US 1997-65728P 19971114 (60)  
US 1998-85538P 19980515 (60)

DT Patent  
FS Granted  
LN.CNT 3638  
INCL INCLM: 564/084.000  
NCL NCLM: 564/084.000  
IC [7]  
ICM: C07C303-00  
EXF 564/84  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 350 OF 367 USPATFULL on STN  
AN 2000:54070 USPATFULL  
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof  
IN Markland, William, Milford, MA, United States  
Ladner, Robert Charles, Ijamsville, MD, United States  
PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)  
PI US 6057287 20000502  
AI US 1994-208264 19940310 (8)  
RLI Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 3820  
INCL INCLM: 514/002.000  
INCLS: 514/012.000; 530/300.000; 530/317.000; 530/324.000; 435/004.000;  
435/007.400; 435/007.720; 435/069.100

NCLS: 435/004.000; 435/007.400; 435/007.720; 435/069.100; 514/012.000;  
530/300.000; 530/317.000; 530/324.000

IC [7]  
ICM: A61K038-16  
ICS: C07K014-00

EXF 530/317; 530/300; 530/324; 514/12; 514/2; 435/69.1; 435/4; 435/7.4;  
435/7.72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 351 OF 367 USPATFULL on STN

AN 2000:28107 USPATFULL

TI .beta.-sheet nucleating peptidomimetics

IN Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United States 77840

PI US 6034211 20000307

AI US 1996-664379 19960614 (8)

PRAI US 1996-18925P 19960603 (60)

DT Utility

FS Granted

LN.CNT 1635

INCL INCLM: 530/317.000

INCLS: 546/101.000

NCL NCLM: 530/317.000

NCLS: 546/101.000

IC [7]  
ICM: C07K005-00

EXF 548/427; 546/101; 514/323-328; 530/317

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 352 OF 367 USPATFULL on STN

AN 2000:15635 USPATFULL

TI Inhibitors of . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* toxicity

IN Kiessling, Laura L., Madison, WI, United States

Murphy, Regina M., Madison, WI, United States

PA Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

PI US 6022859 20000208

AI US 1997-970833 19971114 (8)

PRAI US 1996-30840P 19961115 (60)

DT Utility

FS Granted

LN.CNT 891

INCL INCLM: 514/014.000

INCLS: 514/013.000; 514/015.000; 530/326.000; 530/327.000

NCL NCLM: 514/014.000

NCLS: 514/013.000; 514/015.000; 530/326.000; 530/327.000

IC [6]  
ICM: A61K038-00

EXF 530/326-327; 514/13-15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 353 OF 367 USPATFULL on STN

AN 1999:113631 USPATFULL

TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor

IN Holmes, Todd, Somerville, MA, United States

Zhang, Shuguang, Cambridge, MA, United States

Rich, Alexander, Cambridge, MA, United States

DiPersio, C. Michael, Norton, MA, United States

Lockshin, Curtis, Lexington, MA, United States

PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

PI US 5955343 19990921

AI US 1994-293284 19940822 (8)

RLI Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned

DT Utility

FS Granted

LN.CNT 2516

INCL INCLM: 435/240.100

INCLS: 435/240.200; 435/240.230; 435/240.241

NCL NCLM: 435/325.000

NCLS: 435/378.000; 435/395.000; 435/401.000

IC [6]  
ICM: C12N005-02



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 354 OF 367 USPATFULL on STN  
AN 1999:13026 USPATFULL  
TI Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor  
IN Morser, Michael John, San Francisco, CA, United States  
Nagashima, Mariko, Belmont, CA, United States  
PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)  
PI US 5864018 19990126  
AI US 1996-633148 19960416 (8)  
DT Utility  
FS Granted  
LN.CNT 1960  
INCL INCLM: 530/387.100  
INCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300  
NCL NCLM: 530/387.100  
NCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300  
IC [6]  
ICM: C07K016-00  
EXF 530/387.1; 530/387.3; 530/388.1; 530/388.225; 530/391.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 355 OF 367 USPATFULL on STN  
AN 1998:162469 USPATFULL  
TI A.beta. peptides that modulate . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* aggregation  
IN Findeis, Mark A., Cambridge, MA, United States  
Benjamin, Howard, Lexington, MA, United States  
Garnick, Marc B., Brookline, MA, United States  
Geffer, Malcolm L., Lincoln, MA, United States  
Hundal, Arvind, Brighton, MA, United States  
Kasman, Laura, Athens, GA, United States  
Musso, Gary, Hopkinton, MA, United States  
Signer, Ethan R., Cambridge, MA, United States  
Wakefield, James, Brookline, MA, United States  
Reed, Michael, Marietta, GA, United States  
Molineaux, Susan, Brookline, MA, United States  
Kubasek, William, Belmont, MA, United States  
Chin, Joseph, Salem, MA, United States  
Lee, Jung-Ja, Wayland, MA, United States  
Kelley, Michael, Arlington, MA, United States  
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5854204 19981229  
AI US 1996-612785 19960314 (8)  
RLI Continuation-in-part of Ser. No. US 1995-404831, filed on 14 Mar 1995  
And a continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995  
And a continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct 1995  
DT Utility  
FS Granted  
LN.CNT 4304  
INCL INCLM: 514/002.000  
INCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000  
NCL NCLM: 514/002.000  
NCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000  
IC [6]  
ICM: C07K014-435  
ICS: C07K007-08  
EXF 514/14; 514/12; 514/2; 530/300; 530/324; 530/326; 930/10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 356 OF 367 USPATFULL on STN  
AN 1998:157595 USPATFULL  
TI Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior  
IN Neve, Rachael L., Belmont, MA, United States  
Berger-Sweeney, Joanne, Natick, MA, United States  
PA The McLean Hospital Corporation, Belmont, MA, United States (U.S. corporation)  
Wellesley College, Wellesley, MA, United States (U.S. corporation)  
PI US 5849999 19981215  
AI US 1996-729345 19961016 (8)

FS Granted  
LN.CNT 899  
INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 424/009.100; 435/172.300; 935/060.000  
NCL NCLM: 800/003.000  
NCLS: 424/009.100; 800/012.000; 800/025.000  
IC [6]  
ICM: C12N005-00  
ICS: C12N015-00; A61K049-00  
EXF 800/2; 800/DIG.1; 935/60; 435/172.3; 435/320.1; 536/23.1; 424/9.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 357 OF 367 USPATFULL on STN  
AN 1998:150712 USPATFULL  
TI Method for decomposing amyloid protein precursor and \*\*\*amyloid\*\*\*  
\*\*\*beta\*\*\* -protein  
IN Miyazaki, Kaoru, Kanagawa-ken, Japan  
PA Oriental Yeast Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
PI US 5843695 19981201  
AI US 1996-641774 19960430 (8)  
RLI Division of Ser. No. US 1994-232474, filed on 25 Apr 1994, now abandoned  
PRAI JP 1993-122207 19930427  
JP 1994-51133 19940225  
DT Utility  
FS Granted  
LN.CNT 262  
INCL INCLM: 435/023.000  
INCLS: 435/004.000  
NCL NCLM: 435/023.000  
NCLS: 435/004.000  
IC [6]  
ICM: C12Q001-37  
EXF 424/94.6; 424/94.2; 424/94.67; 424/94.63; 435/4; 435/7.2; 435/7.4;  
435/23; 514/879; 514/2; 514/12; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 358 OF 367 USPATFULL on STN  
AN 1998:143904 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, United States  
Guttermann, Sonia Kosow, Belmont, MA, United States  
Roberts, Bruce Lindsay, Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur Charles, Newton, MA, United States  
Kent, Rachel Baribault, Boxborough, MA, United States  
PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)  
PI US 5837500 19981117  
AI US 1995-415922 19950403 (8)  
RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now  
patented, Pat. No. US 5403484 which is a division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409  
which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2  
Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US  
1988-240160, filed on 2 Sep 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 15973  
INCL INCLM: 435/069.700  
INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400  
NCL NCLM: 435/069.700  
NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;  
536/023.400  
IC [6]  
ICM: C12N015-62  
ICS: C07K019-00  
EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 359 OF 367 USPATFULL on STN  
AN 97:86591 USPATFULL  
TI Stable macroscopic membranes formed by self-assembly of amphiphilic  
peptides and uses therefor  
IN Zhang, Shuguang, Cambridge, MA, United States  
Lockshin, Curtis, Lexington, MA, United States  
Rich, Alexander, Cambridge, MA, United States

PA Massachusetts Insititute of Technology, Cambridge, MA, United States  
(U.S. corporation)  
PI US 5670483 19970923  
AI US 1994-346849 19941130 (8)  
RLI Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 2210  
INCL INCLM: 514/014.000  
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;  
530/326.000; 530/327.000; 530/350.000  
NCL NCLM: 514/014.000  
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;  
530/326.000; 530/327.000; 530/350.000  
IC [6]  
ICM: A61K007-08  
ICS: A61K014-00; C07K038-10; C07K038-16  
EXF 530/300; 530/350; 514/12; 514/13; 514/14  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 360 OF 367 USPATFULL on STN  
AN 96:108822 USPATFULL  
TI Methods and systems for screening potential alzheimer's disease  
therapeutics  
IN Nishimoto, Ikuo, Brookline, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S.  
corporation)  
PI US 5578451 19961126  
AI US 1995-371930 19950112 (8)  
RLI Continuation of Ser. No. US 1993-19208, filed on 18 Feb 1993, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 1339  
INCL INCLM: 435/007.100  
INCLS: 435/007.200; 435/007.210; 435/975.000  
NCL NCLM: 435/007.100  
NCLS: 435/007.200; 435/007.210; 435/975.000  
IC [6]  
ICM: G01N033-53  
ICS: G01N033-567  
EXF 435/6; 435/7.2; 435/7.21; 435/7.1; 436/518; 436/536  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 361 OF 367 USPATFULL on STN  
AN 96:101466 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States  
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S.  
corporation)  
PI US 5571698 19961105  
AI US 1993-57667 19930618 (8)  
RLI Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now  
patented, Pat. No. US 5223409 which is a continuation-in-part of Ser.  
No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a  
continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 15323  
INCL INCLM: 435/069.700  
INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100  
NCL NCLM: 435/069.700  
NCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000  
IC [6]  
ICM: C12N025-62  
EXF 435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:77867 USPATFULL  
 TI Gelatinase A inhibitor, and analytical reagent thereof for the  
 determination of gelatinase A  
 IN Miyazaki, Kaoru, Kanagawa-ken, Japan  
 PA Oriental Yeast Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
 PI US 5550216 19960827  
 AI US 1994-231940 19940425 (8)  
 PRAI JP 1993-120457 19930426  
 JP 1994-62129 19940308  
 DT Utility  
 FS Granted  
 LN.CNT 367  
 INCL INCLM: 530/395.000  
 INCLS: 530/324.000; 530/354.000; 530/355.000; 530/828.000; 436/064.000;  
 436/086.000; 436/087.000  
 NCL NCLM: 530/395.000  
 NCLS: 436/064.000; 436/086.000; 436/087.000; 530/324.000; 530/354.000;  
 530/355.000; 530/828.000  
 IC [6]  
 ICM: C07K017-00  
 ICS: A61K038-00; G01N033-00  
 EXF 530/395; 530/324; 530/354; 530/355; 530/828; 514/12; 514/21; 435/39;  
 436/64; 436/86; 436/87  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 363 OF 367 USPATFULL on STN  
 AN 93:52487 USPATFULL  
 TI Directed evolution of novel binding proteins  
 IN Ladner, Robert C., Ijamsville, MD, United States  
 Guterman, Sonia K., Belmont, MA, United States  
 Roberts, Bruce L., Milford, MA, United States  
 Markland, William, Milford, MA, United States  
 Ley, Arthur C., Newton, MA, United States  
 Kent, Rachel B., Boxborough, MA, United States  
 PA Protein Engineering Corp., Cambridge, MA, United States (U.S.  
 corporation)  
 PI US 5223409 19930629  
 AI US 1991-664989 19910301 (7)  
 RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
 now abandoned And a continuation-in-part of Ser. No. US 1988-240160,  
 filed on 2 Sep 1988, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 15410  
 INCL INCLM: 435/069.700  
 INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300;  
 530/387.500  
 NCL NCLM: 435/069.700  
 NCLS: 435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000;  
 530/387.300; 530/387.500  
 IC [5]  
 ICM: C12N015-09  
 ICS: C12N015-62; C12N015-63  
 EXF 435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 364 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2003-804023 [75] WPIDS  
 CR 2003-876973 [81]  
 DNC C2003-221996  
 TI Controlling self-assembly of peptide-based structures (e.g. nanotubes)  
 comprises providing a controlled environment and placing segments of  
 \*\*\*beta\*\*\* - \*\*\*amyloids\*\*\* in the controlled environment to generate  
 a self-assembling structure.  
 DC A89 B04 D16  
 IN LI, X; LYNN, D; CONTICELLO, V; DONG, J; MORGAN, D A  
 PA (LIXX-I) LI X; (LYNN-I) LYNN D; (UYEM-N) UNIV EMORY  
 CYC 103  
 PI WO 2003082900 A2 20031009 (200375)\* EN 46 C07K000-00  
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS  
 LU MC MW NZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL  
 PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA

US 2003215853 A1 20031120 (200377) C12Q001-68  
 AU 2003226007 A1 20031013 (200435) C07K000-00  
 ADT WO 2003082900 A2 WO 2003-US9229 20030324; US 2003215853 A1 Provisional US  
 2002-366870P 20020322, Provisional US 2002-420533P 20021023, Provisional  
 US 2003-456641P 20030321, US 2003-396001 20030324; AU 2003226007 A1 AU  
 2003-226007 20030324  
 FDT AU 2003226007 A1 Based on WO 2003082900  
 PRAI US 2003-456641P 20030321; US 2002-366826P 20020322;  
 US 2002-420746P 20021023; US 2002-366870P 20020322;  
 US 2002-420533P 20021023; US 2003-396001 20030324  
 IC ICM C07K000-00; C12Q001-68  
 ICS C07H021-04; C08G063-48  
  
 L5 ANSWER 365 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2003-712557 [67] WPIDS  
 DNC C2003-195932  
 TI New helical peptidomimetic compounds, useful for preparing medicaments for  
 treating subject having or at risk of having a \*\*\*Beta\*\*\* -  
 \*\*\*amyloid\*\*\* -associated disease, e.g. Alzheimer's disease or Down's  
 syndrome.  
 DC B04  
 IN WOLFE, M S  
 PA (BGHM) BRIGHAM & WOMENS HOSPITAL INC  
 CYC 29  
 PI WO 2003068168 A2 20030821 (200367)\* EN 44 A61K000-00  
 RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE  
 SI SK TR  
 W: AU CA JP  
 US 2003186877 A1 20031002 (200372) A61K038-16  
 AU 2003217543 A1 20030904 (200428) A61K000-00  
 ADT WO 2003068168 A2 WO 2003-US4683 20030214; US 2003186877 A1 Provisional US  
 2002-357023P 20020214, US 2003-367599 20030214; AU 2003217543 A1 AU  
 2003-217543 20030214  
 FDT AU 2003217543 A1 Based on WO 2003068168  
 PRAI US 2002-357023P 20020214; US 2003-367599 20030214  
 IC ICM A61K000-00; A61K038-16  
 ICS A61K038-04; A61K038-06; A61K038-08; A61K038-10; C07K005-04;  
 C07K005-06; C07K007-06; C07K007-08  
  
 L5 ANSWER 366 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2003-342445 [32] WPIDS  
 DNC C2003-089818  
 TI Chemical compound for use in diagnosing or treating Alzheimer's disease,  
 comprises multiple copies of a plaque-recognition peptide and is capable  
 of crossing blood brain-barrier.  
 DC B04 D16 K08  
 IN STEIN, S  
 PA (STEI-I) STEIN S  
 CYC 101  
 PI WO 2003018609 A2 20030306 (200332)\* EN 37 C07K000-00  
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU  
 MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT  
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA  
 ZM ZW  
 AU 2002327514 A1 20030310 (200452) C07K000-00  
 ADT WO 2003018609 A2 WO 2002-US26889 20020823; AU 2002327514 A1 AU 2002-327514  
 20020823  
 FDT AU 2002327514 A1 Based on WO 2003018609  
 PRAI US 2001-314382P 20010823  
 IC ICM C07K000-00  
  
 L5 ANSWER 367 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 1991-295576 [40] WPIDS  
 DNC C1991-127779  
 TI New chymotrypsin-like serine protease(s) - and their inhibitors are used  
 to treat Alzheimer's disease.  
 DC B04 D16  
 IN KAUER, J C; NELSON, R B N; POTTER, H; SIMAN, R; NELSON, R B; KAUER, J  
 PA (CEPH-N) CEPHALON INC  
 CYC 35  
 PI WO 9113904 A 19910919 (199140)\*  
 RW: AT BE CH DE DK ES FR GB GR IT LU NL OA SE

AU 9174654	A	19911010	(199201)		
ZA 9101607	A	19911224	(199205)		
FI 9203983	A	19920904	(199249)		C12N000-00
EP 518955	A1	19921223	(199252)	EN 86	C07K003-00
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
NO 9203469	A	19921104	(199306)		C12N009-00
HU 62312	T	19930428	(199322)		C07K003-00
JP 05506777	W	19931007	(199345)		C12N009-64
EP 518955	A4	19930922	(199527)		
AU 661270	B	19950720	(199537)		C12N009-64
EP 732399	A2	19960918	(199642)	EN 54	C12N009-64
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
EP 732399	A3	19970312	(199722)		
ADT	ZA 9101607 A ZA 1991-1607 19910705; FI 9203983 A WO 1991-US1474 19910304,				
	FI 1992-3983 19920904; EP 518955 A1 EP 1991-905743 19910304, WO				
	1991-US1474 19910304; NO 9203469 A WO 1991-US1474 19910304, NO 1992-3469				
	19920904; HU 62312 T WO 1991-US1474 19910304, HU 1992-2842 19910304; JP				
	05506777 W JP 1991-506146 19910304, WO 1991-US1474 19910304; EP 518955 A4				
	EP 1991-905743 ; AU 661270 B AU 1991-74654 19910304; EP 732399 A2				
	Div ex EP 1991-905743 19910304, EP 1996-103933 19910304; EP 732399 A3 Div				
	ex EP 1991-905743 19910304, EP 1996-103933 19910304				
FDT	EP 518955 A1 Based on WO 9113904; HU 62312 T Based on WO 9113904; JP				
	05506777 W Based on WO 9113904; AU 661270 B Previous Publ. AU 9174654,				
	Based on WO 9113904				
PRAI	US 1990-489290 19900305				
IC	ICM C07K003-00; C12N000-00; C12N009-00; C12N009-64				
	ICS A23J001-00; A61K037-64; A61K038-04; C07K005-00; C07K005-06;				
	C07K005-08; C07K005-10; C07K007-00; C07K007-06; C07K017-00;				
	C07K017-02; C12Q001-37; G01N033-564				
STN	INTERNATIONAL LOGOFF AT 12:25:25 ON 30 AUG 2004				